



US 20250263698A1

(19) **United States**

(12) **Patent Application Publication**

BAHNEY et al.

(10) **Pub. No.: US 2025/0263698 A1**

(43) **Pub. Date:** **Aug. 21, 2025**

(54) **EXOSOME THERAPY AND PROCESS TO
IMPROVE FORMULATION AND
PRODUCTION**

(71) Applicants: **STEADMAN PHILIPPON
RESEARCH INSTITUTE**, Vail, CO
(US); **COLORADO STATE
UNIVERSITY RESEARCH
FOUNDATION (CSURF)**, Fort
Collins, CO (US)

(72) Inventors: **Chelsea BAHNEY**, Vail, CO (US);
Nicole EHRHART, Ft. Collins, CO
(US); **Michael Terrance MULLEN, II**,
Vail, CO (US); **Johnny HUARD**, Vail,
CO (US)

(21) Appl. No.: **18/692,770**

(22) PCT Filed: **Sep. 16, 2022**

(86) PCT No.: **PCT/US2022/076580**

§ 371 (c)(1),
(2) Date: **Mar. 15, 2024**

Related U.S. Application Data

(60) Provisional application No. 63/245,729, filed on Sep.
17, 2021.

Publication Classification

(51) **Int. Cl.**
C12N 15/113 (2010.01)
A61K 9/50 (2006.01)

(52) **U.S. Cl.**
CPC *C12N 15/113* (2013.01); *A61K 9/5068*
(2013.01); *C12N 2310/141* (2013.01)

(57) ABSTRACT

The present disclosure provides compositions comprising exosomes comprising mechanoresponsive miRNAs and uses of the compositions. The disclosure also provides methods for preparing compositions comprising exosomes comprising mechanoresponsive miRNAs.

Specification includes a Sequence Listing.




FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F




FIG. 2G





FIG. 2I




FIG. 3




FIG. 4A




FIG. 4B

	Fold change
- Exo	0
+ Static Exo	0.366
+ HSSD Exo	1.018
+ LSBD Exo	1.827

FIG. 4C




FIG. 4D






FIG. 4E




- Exo

FIG. 4F




+ Static Exo

FIG. 4G



+ HSSD Exo

FIG. 4H



+ LSLD Exo

FIG. 4I

Tukey's multiple comparisons test		Summary	Adjusted P value
0			
Static vs. HSSD	ns	>0.9999	
Static vs. LSLD	ns	>0.9999	
HSSD vs. LSLD	ns	>0.9999	
1			
Static vs. HSSD	**	0.0024	
Static vs. LSLD	****	<0.0001	
HSSD vs. LSLD	****	<0.0001	
2			
Static vs. HSSD	****	<0.0001	
Static vs. LSLD	****	<0.0001	
HSSD vs. LSLD	ns	0.9938	
3			
Static vs. HSSD	****	<0.0001	
Static vs. LSLD	****	<0.0001	
HSSD vs. LSLD	ns	0.9938	




FIG. 5A

ANOVA table	F (DFn, DFd)	P value
Time x group factor	F (6, 45) = 10.20	P<0.0001
Time	F (1,430, 21,46) = 417.1	P<0.0001
Group factor	F (2, 15) = 38.94	P<0.0001
Subject	F (15, 45) = 1.681	P=0.0901

FIG. 5C

FIG. 5B

	Tukey's multiple comparisons test	Summary	Adjusted P value
1			
Control vs. static	ns		0.8683
Control vs. HSSD	ns		0.9987
Control vs. LSLD	ns		0.8279
Static vs. HSSD	ns		0.4008
Static vs. LSLD	ns		0.1054
HSSD vs. LSLD	*		0.047
3			
Control vs. static	ns		0.2411
Control vs. HSSD	***		0.0004
Control vs. LSLD	**		0.0027
Static vs. HSSD	ns		0.3362
Static vs. LSLD	**		0.0059
HSSD vs. LSLD	*		0.0279
		5	
Control vs. static	ns		0.227
Control vs. HSSD	***		0.0004
Control vs. LSLD	**		0.0012
Static vs. HSSD	ns		0.5896
Static vs. LSLD	*		0.0411
HSSD vs. LSLD	ns		0.0818




FIG. 6A

ANOVA table	F (DFn, DFd)	P value
Time × group	F (6, 40) = 12.79	P<0.0001
Time	F (1.476, 29.52) = 187.8	P<0.0001
Group factor	F (3, 20) = 12.37	P<0.0001
Subject	F (20, 450) = 2.167	P=0.0185

FIG. 6C

FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E

HSSD v Static Enriched GO Terms			
GO Term	Description	P-value	FDR q-value
GO:0048522	Positive regulation of cellular process	4.60E-10	6.75E-06
GO:0014013	Regulation of gliogenesis	7.74E-09	5.68E-05
GO:0048518	Positive regulation of biological process	1.42E-08	6.95E-05
GO:0023051	Regulation of signaling	4.40E-08	1.61E-04
GO:0080090	Regulation of primary metabolic process	5.39E-08	1.58E-04
GO:0010646	Regulation of cell communication	9.14E-08	2.24E-04
GO:0051239	Regulation of multicellular organismal process	1.14E-07	2.38E-04
GO:0032502	Developmental process	1.38E-07	2.52E-04
GO:0019219	Regulation of nucleobase-containing compound metabolic process	1.78E-07	2.90E-04
GO:0031323	Regulation of cellular metabolic process	2.06E-07	3.02E-04
GO:0019222	Regulation of metabolic process	2.22E-07	2.97E-04
GO:0051252	Regulation of RNA metabolic process	3.46E-07	4.24E-04
GO:0031326	Regulation of cellular biosynthetic process	4.02E-07	4.53E-04
GO:0051171	Regulation of nitrogen compound metabolic process	4.87E-07	5.11E-04
GO:0099177	Regulation of trans-synaptic signalling	5.98E-07	5.85E-04
GO:0050804	Modulation of chemical synaptic transmission	5.98E-07	5.49E-04
GO:0010468	Regulation of gene expression	8.13E-07	7.02E-04
GO:0009889	Regulation of biosynthetic process	8.55E-07	6.97E-04
GO:2000112	Regulation of cellular macromolecule biosynthetic process	9.28E-07	7.17E-04
GO:0060255	Regulation of macromolecule metabolic process	9.86E-07	7.24E-04
GO:0048869	Cellular developmental process	1.13E-06	7.90E-04
GO:0010556	Regulation of macromolecule biosynthetic process	1.43E-06	9.53E-04
GO:0009653	Anatomical structure morphogenesis	1.43E-06	9.13E-04
GO:0031325	Positive regulation of cellular metabolic process	1.66E-06	1.01E-03
GO:0048167	Regulation of synaptic plasticity	1.79E-06	1.05E-03
GO:0045685	Regulation of glial cell differentiation	2.87E-06	1.62E-03
GO:0051049	Regulation of transport	2.88E-06	1.56E-03
GO:0010647	Positive regulation of cell communication	2.96E-06	1.55E-03
GO:0050793	Regulation of developmental process	3.15E-06	1.59E-03
GO:0009893	Positive regulation of metabolic process	3.16E-06	1.55E-03
GO:0023056	Positive regulation of signaling	3.29E-06	1.56E-03
GO:0032879	Regulation of localization	4.58E-06	2.10E-03
GO:0014015	Positive regulation of gliogenesis	5.01E-06	2.23E-03
GO:0006355	Regulation of transcription, DNA-templated	5.01E-06	2.16E-03
GO:0003012	Muscle system process	5.22E-06	2.19E-03

FIG. 8 (page 1 of 6)

HSSD v Static Enriched GO Terms			
GO Term	Description	P-value	FDR q-value
GO:1903506	Regulation of nucleic acid-templated transcription	5.28E-06	2.15E-03
GO:2001141	Regulation of RNA biosynthetic process	5.71E-06	2.26E-03
GO:0048856	Anatomical structure development	6.40E-06	2.47E-03
GO:0009966	Regulation of signal transduction	6.50E-06	2.45E-03
GO:0006357	Regulation of transcription by RNA polymerase II	6.99E-06	2.56E-03
GO:0048713	Regulation of oligodendrocyte differentiation	7.90E-06	2.83E-03
GO:0016043	Cellular component organization	8.89E-06	3.11E-03
GO:0044093	Positive regulation of molecular function	9.45E-06	3.23E-03
GO:0043085	Positive regulation of catalytic activity	1.02E-05	3.40E-03
GO:1903530	Regulation of secretion by cell	1.10E-05	3.60E-03
GO:0065008	Regulation of biological quality	1.14E-05	3.64E-03
GO:0051173	Positive regulation of nitrogen compound metabolic process	1.19E-05	3.72E-03
GO:0008277	Regulation of G protein-coupled receptor signaling pathway	1.35E-05	4.12E-03
GO:0071840	Cellular component organization or biogenesis	1.80E-05	5.40E-03
GO:0051345	Positive regulation of hydrolase activity	1.83E-05	5.38E-03
GO:0030154	Cell differentiation	1.94E-05	5.57E-03
GO:0045935	Positive regulation of nucleobase-containing compound metabolic process	2.08E-05	5.87E-03
GO:0007610	Behavior	2.19E-05	6.07E-03
GO:0060284	Regulation of cell development	2.46E-05	6.68E-03
GO:0043547	Positive regulation of GTPase activity	2.63E-05	7.03E-03
GO:0043087	Regulation of GTPase activity	2.84E-05	7.45E-03
GO:0010629	Negative regulation of gene expression	3.03E-05	7.82E-03
GO:0045595	Regulation of cell differentiation	3.48E-05	8.80E-03
GO:0010605	Negative regulation of macromolecule metabolic process	3.50E-05	8.70E-03
GO:0030900	Forebrain development	3.60E-05	8.81E-03
GO:1904951	Positive regulation of establishment of protein localization	3.97E-05	9.56E-03
GO:0051254	Positive regulation of RNA metabolic process	4.40E-05	1.04E-02
GO:0051726	Regulation of cell cycle	4.58E-05	1.07E-02
GO:0065007	Biological regulation	4.71E-05	1.08E-02
GO:0051046	Regulation of secretion	4.72E-05	1.07E-02
GO:0010604	Positive regulation of macromolecule metabolic process	4.74E-05	1.05E-02
GO:0048812	Neuron projection morphogenesis	5.03E-05	1.10E-02
GO:0048519	Negative regulation of biological process	5.13E-05	1.11E-02
GO:0045597	Positive regulation of cell differentiation	5.24E-05	1.11E-02
GO:0050789	Regulation of biological process	5.72E-05	1.20E-02

FIG. 8 (page 2 of 6)

HSSD v Static Enriched GO Terms			
GO Term	Description	P-value	FDR q-value
GO:0120039	Plasma membrane bounded cell projection morphogenesis	6.24E-05	1.29E-02
GO:0050794	Regulation of cellular process	7.03E-05	1.43E-02
GO:0048858	Cell projection morphogenesis	7.38E-05	1.48E-02
GO:0031327	Negative regulation of cellular biosynthetic process	7.71E-05	1.53E-02
GO:0051093	Negative regulation of developmental process	7.81E-05	1.53E-02
GO:0060251	Regulation of glial cell proliferation	8.71E-05	1.68E-02
GO:0051172	Negative regulation of nitrogen compound metabolic process	8.93E-05	1.70E-02
GO:0051222	Positive regulation of protein transport	9.42E-05	1.77E-02
GO:0050890	Cognition	9.68E-05	1.80E-02
GO:0048513	Animal organ development	1.03E-04	1.90E-02
GO:0051241	Negative regulation of multicellular organismal process	1.05E-04	1.90E-02
GO:0010720	Positive regulation of cell development	1.12E-04	2.00E-02
GO:2000026	Regulation of multicellular organismal development	1.22E-04	2.16E-02
GO:0060627	Regulation of vesicle-mediated transport	1.23E-04	2.14E-02
GO:0042325	Regulation of phosphorylation	1.23E-04	2.13E-02
GO:0022603	Regulation of anatomical structure morphogenesis	1.25E-04	2.13E-02
GO:0008283	Cell proliferation	1.25E-04	2.11E-02
GO:0009890	Negative regulation of biosynthetic process	1.26E-04	2.11E-02
GO:0051240	Positive regulation of multicellular organismal process	1.27E-04	2.10E-02
GO:0010611	Regulation of cardiac muscle hypertrophy	1.28E-04	2.09E-02
GO:0070201	Regulation of establishment of protein localization	1.36E-04	2.19E-02
GO:0007611	Learning or memory	1.39E-04	2.22E-02
GO:0017158	Regulation of calcium ion-dependent exocytosis	1.40E-04	2.20E-02
GO:0048523	Negative regulation of cellular process	1.40E-04	2.18E-02
GO:0045944	Positive regulation of transcription by RNA polymerase II	1.40E-04	2.16E-02
GO:0014743	Regulation of muscle hypertrophy	1.41E-04	2.16E-02
GO:0045893	Positive regulation of transcription, DNA-templated	1.48E-04	2.25E-02
GO:1903508	Positive regulation of nucleic acid-templated transcription	1.48E-04	2.22E-02
GO:0051094	Positive regulation of developmental process	1.50E-04	2.22E-02
GO:1902680	Positive regulation of RNA biosynthetic process	1.51E-04	2.21E-02
GO:0035239	Tube morphogenesis	1.56E-04	2.26E-02
GO:0051128	Regulation of cellular component organization	1.66E-04	2.39E-02
GO:0032970	Regulation of actin filament-based process	1.70E-04	2.42E-02
GO:0048583	Regulation of response to stimulus	1.73E-04	2.45E-02
GO:1902531	Regulation of intracellular signal transduction	1.73E-04	2.42E-02
GO:0032990	Cell part morphogenesis	1.74E-04	2.41E-02

FIG. 8 (page 3 of 6)

HSSD v Static Enriched GO Terms			
GO Term	Description	P-value	FDR q-value
GO:0090087	Regulation of peptide transport	1.77E-04	2.42E-02
GO:0009968	Negative regulation of signal transduction	1.82E-04	2.47E-02
GO:0002025	Norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	1.82E-04	2.45E-02
GO:0019220	Regulation of phosphate metabolic process	1.97E-04	2.63E-02
GO:0051174	Regulation of phosphorus metabolic process	1.99E-04	2.64E-02
GO:0030510	Regulation of BMP signaling pathway	2.03E-04	2.67E-02
GO:0030036	Actin cytoskeleton organization	2.29E-04	2.97E-02
GO:0051223	Regulation of protein transport	2.29E-04	2.95E-02
GO:0007010	Cytoskeleton organization	2.31E-04	2.94E-02
GO:0030513	Positive regulation of BMP signaling pathway	2.35E-04	2.97E-02
GO:1903305	Regulation of regulated secretory pathway	2.36E-04	2.97E-02
GO:0009892	Negative regulation of metabolic process	2.45E-04	3.05E-02
GO:0001932	Regulation of protein phosphorylation	2.49E-04	3.07E-02
GO:0040013	Negative regulation of locomotion	2.58E-04	3.15E-02
GO:0048715	Negative regulation of oligodendrocyte differentiation	2.73E-04	3.31E-02
GO:0065009	Regulation of molecular function	3.00E-04	3.61E-02
GO:2000113	Negative regulation of cellular macromolecule biosynthetic process	3.10E-04	3.70E-02
GO:0032989	Cellular component morphogenesis	3.12E-04	3.70E-02
GO:0010001	Glial cell differentiation	3.36E-04	3.94E-02
GO:2000027	Regulation of animal organ morphogenesis	3.45E-04	4.02E-02
GO:0050714	Positive regulation of protein secretion	3.49E-04	4.03E-02
GO:0031328	Positive regulation of cellular biosynthetic process	3.57E-04	4.09E-02
GO:0044057	Regulation of system process	3.60E-04	4.10E-02
GO:0042060	Wound healing	3.63E-04	4.10E-02
GO:1905879	Regulation of oogenesis	3.71E-04	4.16E-02
GO:0060281	Regulation of oocyte development	3.71E-04	4.13E-02
GO:0010558	Negative regulation of macromolecule biosynthetic process	3.72E-04	4.11E-02
GO:0010648	Negative regulation of cell communication	3.75E-04	4.11E-02
GO:0007275	Multicellular organism development	3.81E-04	4.14E-02
GO:1904646	Cellular response to amyloid-beta	3.84E-04	4.15E-02
GO:0048710	Regulation of astrocyte differentiation	3.84E-04	4.12E-02
GO:0043410	Positive regulation of MAPK cascade	3.85E-04	4.09E-02
GO:0006996	Organelle organization	3.86E-04	4.07E-02
GO:0023057	Negative regulation of signaling	3.87E-04	4.06E-02


FIG. 8 (page 4 of 6)

HSSD v Static Enriched GO Terms			
GO Term	Description	P-value	FDR q-value
GO:0030030	Cell projection organization	4.02E-04	4.18E-02
GO:0001763	Morphogenesis of a branching structure	4.29E-04	4.44E-02
GO:0060537	Muscle tissue development	4.39E-04	4.51E-02
GO:0017157	Regulation of exocytosis	4.49E-04	4.57E-02
GO:0009967	Positive regulation of signal transduction	4.58E-04	4.63E-02
GO:0060688	Regulation of morphogenesis of a branching structure	4.60E-04	4.62E-02
GO:0051050	Positive regulation of transport	4.77E-04	4.76E-02
GO:0031324	Negative regulation of cellular metabolic process	4.77E-04	4.73E-02
GO:0010557	Positive regulation of macromolecule biosynthetic process	4.97E-04	4.89E-02
GO:0046579	Positive regulation of Ras protein signal transduction	5.06E-04	4.96E-02
GO:0043502	Regulation of muscle adaptation	5.27E-04	5.12E-02
GO:0009891	Positive regulation of biosynthetic process	5.31E-04	5.13E-02
GO:0043065	Positive regulation of apoptotic process	5.32E-04	5.10E-02
GO:0033674	Positive regulation of kinase activity	5.36E-04	5.11E-02
GO:2000843	Regulation of testosterone secretion	5.41E-04	5.12E-02
GO:0045967	Negative regulation of growth rate	5.41E-04	5.09E-02
GO:1901700	Response to oxygen-containing compound	5.60E-04	5.24E-02
GO:0043068	Positive regulation of programmed cell death	5.81E-04	5.40E-02
GO:0002026	Regulation of the force of heart contraction	5.91E-04	5.46E-02
GO:0010660	Regulation of muscle cell apoptotic process	6.07E-04	5.57E-02
GO:0043900	Regulation of multi-organism process	6.36E-04	5.80E-02
GO:0010942	Positive regulation of cell death	6.54E-04	5.93E-02
GO:0030336	Negative regulation of cell migration	7.02E-04	6.32E-02
GO:0051246	Regulation of protein metabolic process	7.10E-04	6.35E-02
GO:0043408	Regulation of MAPK cascade	7.10E-04	6.31E-02
GO:1904645	Response to amyloid-beta	7.67E-04	6.78E-02
GO:0043567	Regulation of insulin-like growth factor receptor signaling pathway	7.94E-04	6.98E-02
GO:0010721	Negative regulation of cell development	8.31E-04	7.26E-02
GO:0043549	Regulation of kinase activity	8.34E-04	7.24E-02
GO:0060078	Regulation of postsynaptic membrane potential	8.65E-04	7.47E-02
GO:0034762	Regulation of transmembrane transport	8.79E-04	7.55E-02
GO:0051347	Positive regulation of transferase activity	9.18E-04	7.84E-02
GO:0030029	Actin filament-based process	9.28E-04	7.88E-02
GO:0051057	Positive regulation of small GTPase mediated signal transduction	9.40E-04	7.93E-02

FIG. 8 (page 5 of 6)

HSSD v Static Enriched GO Terms			
GO Term	Description	P-value	FDR q-value
GO:2000146	Negative regulation of cell motility	9.60E-04	8.60E-02
GO:2000300	Regulation of synaptic vesicle exocytosis	9.62E-04	8.03E-02
GO:0048738	Cardiac muscle tissue development	9.77E-04	8.10E-02
GO:0001525	Angiogenesis	9.94E-04	8.19E-02

FIG. 8 (page 6 of 6)

**FIG. 9A**




FIG. 9B




FIG. 9C

EXOSOME THERAPY AND PROCESS TO IMPROVE FORMULATION AND PRODUCTION

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is being filed on Sep. 16, 2022, as a PCT International Patent Application that claims priority to and the benefit of U.S. Provisional Patent Application No. 63/245,729, filed Sep. 17, 2021, the entire content of which is incorporated by reference herein.

FIELD OF THE DISCLOSURE

[0002] The present disclosure is related to compositions comprising exosomes comprising mechanoresponsive miRNAs and uses of the compositions. The disclosure is also related to methods for preparing compositions comprising exosomes comprising mechanoresponsive miRNAs.

REFERENCE TO A SEQUENCE LISTING XML

[0003] The instant application contains a Sequence Listing, which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Sep. 16, 2022, is named 18472_0022WOU1_SL.xml and is 58,366 bytes in size.

BACKGROUND OF THE DISCLOSURE

[0004] Stem cell therapy transformed the field of regenerative medicine over the past several decades, as stem and progenitor cells have been utilized for a wide variety of therapeutic applications including the treatment of cardiovascular (Goradel, et al., 2021 *J Cell Biochem* 119 (1): 95-104), neurologic (Alessandrini, et al., 2019 *South African Med J* 109: 8b), and orthopedic (Grayson, et al., 2015 *Nat Rev Endocrinol* 11 (3): 140-150) diseases. While it was originally thought that stem cells impart their regenerative function by direct differentiation into new tissue, it is now widely accepted that the beneficial effects of stem and progenitor cells can largely be attributed to their paracrine activities (Gnechi, et al., 2008 *Circ Res* 103 (11): 1204-1219; Baraniak and McDevitt, 2010 *Regen Med* 5 (1): 121-143; Huard, 2019 *J Orthop Res* 37 (6)). Mesenchymal stem cells (MSCs) are capable of releasing bioactive molecules, including immunomodulatory and trophic factors, to establish a microenvironment that promotes tissue repair and regeneration by resident cells (Caplan and Correa, 2011 *Cell Stem Cell* 9 (1); Caplan, 2009 *Tissue Eng—Pt B Rev* 15 (2): 195-200). In support of this concept, less than 1% of administered MSCs remain viable up to one week following intravenous injection (Eggenhofer, et al., 2012 *Front Immunol* 3 (SEP); Lee, et al., 2009 *Cell Stem Cell* 5 (1): 54-63) and do not readily differentiate *in vivo* (Caplan, 2017 *Stem Cells Transl Med* 6 (6)), suggesting that the paracrine functions of MSCs are responsible for the benefits of MSC administration (Parekkadan and Milwid, 2010 *Ann Rev Biomed Eng* 12:87-117).

[0005] Extracellular vesicles produced by MSCs have also been recognized as a major source of these pro-regenerative paracrine functions (Rani, et al., 2015 *Mol Ther* 23 (5): 812-823; Wiklander, et al., 2019 *Sci Transl Med* 11 (492): 8521). Exosomes, a subtype of extracellular vesicles that have garnered significant interest in recent years, originate within intracellular multivesicular bodies and are released

into the extracellular space as nanosized (30-150 nm) membrane-bound vesicles upon fusion with the cell membrane. These exosomes can either be endocytosed by nearby cells or can enter circulation to be transported throughout the body. Exosomes contain diverse cargo including nucleic acids, proteins, and lipids, many of which are biologically active and can alter the function of recipient cells. This exosomal cargo is dependent on the cell type of origin, as well as the local microenvironment and physiological state of the originating cell (Phinney and Pittenger, 2017 *Stem Cells* 35 (4): 851-858). A notable component of exosomes includes micro-RNAs (miRNAs), which are small, 20-25-nucleotide RNAs that act as negative regulators of gene expression by binding the 3'UTR of mRNAs to inhibit translation and modulate cell function (Zhang, et al., 2015 *Proteomics Bioinforma* 13 (1): 17-24; Kalluri and LeBleu, 2020 *Science* 80 (367): 6478).

[0006] The ability of exosomes to deliver bioactive molecules to cells has been widely recognized for its therapeutic potential. Within the field of regenerative medicine, exosomes hold several advantages over traditional cell-based therapies. Exosomes can be isolated from desirable cell types, such as MSCs, or can be engineered to contain pro-regenerative miRNAs and other beneficial cargo to promote specified biological functions upon administration to a patient. In contrast to stem cell therapy, exosomes are currently understood to have minimal to no risk of immune rejection (Yu, et al., 2014 *Int J Mol Sci* 15 (3): 4142-4157). Exosomes are also non-dividing and cannot directly form tumors, whereas stem cells may have a tumorigenic potential (Lazennec and Jorgensen, 2008 *Stem Cells* 26 (6): 1387-1394). Additionally, the use of MSCs as a therapeutic presents several manufacturing and regulatory challenges that exosomes may circumvent (Mendt, et al., 2019 *Bone Marrow Transplant* 54 (2): 789-792), thus presenting an alternative therapeutic that replicates the benefits of stem cell therapy while minimizing the associated risks and manufacturing challenges.

[0007] One such area where exosomes hold therapeutic promise is musculoskeletal regeneration (Williams and Ehrhart, 2022 *J Am Vet Med Assoc* 260 (7): 683-689). During aging, the tissue quality and regenerative capacity of skeletal muscle and bone are severely compromised (Carosio, et al., 2011 *Aging Res Rev* 10 (1); Domingues-Faria, et al., 2016 *Aging Res Rev* 26). This contributes to age-related muscle loss and dysfunction, termed sarcopenia, as well as osteoporosis, which together are linked to frailty, increased risk of fracture, and increased mortality (Fielding, et al., 2011 *J Am Med Dir Assoc* 12 (4): 249-256). Cellular crosstalk between muscle and bone is known to occur, as sarcopenia and osteoporosis frequently occur together (Reginster, et al., 2016 *Curr Opin Clin Nutr Metab Care* 19 (1); Edwards, et al., 2015 *Bone* 80:126-130). Moreover, it has been demonstrated that paracrine factors released from skeletal muscle and muscle stem cells contribute to bone fracture repair (Julien, et al., 2021 *Nat Commun* 12 (1); Abou-Khalil, et al., 2015 *Stem Cells* 33 (5): 1501-1511).

[0008] Within the next 30 years, the global population of individuals aged 65 and over is projected to double, reaching 1.5 billion by the year 2050. To meet the medical challenges faced by an aging population, it is critical to develop therapeutics that promote the maintenance, repair, and regeneration of muscle and bone. While resistance exercise is an effective strategy to maintain bone density (Benedetti,

et al., 2018 *Biomed Res Int* <https://pubmed.ncbi.nlm.nih.gov/30671455/>) and skeletal muscle function during the aging process (Vincent, et al., 2002 *J Am Geriatr Soc* 50 (6): 1100-1107; Law, et al., 2016 *Ann Rev Gerontol Geriatr* 36 (1)), there are currently no available pharmacological options to mitigate the age-related decline in muscle regenerative capacity. Mechanical strain of skeletal muscle has been hypothesized to mediate the benefits of resistance exercise on the functional capacity of muscle (Ambrosio, et al., 2009 *Am J Phys Med Rehab* 88 (2)). Additionally, several studies have shown that in vivo mechanical strain improves muscle regeneration and functional recovery following injury (Cezar, et al., 2016 *PNAS USA* 113 (6): 1534-1539; Ambrosio, et al., 2010 *Tissue Eng—Pt A* 16 (3): 839-849; Kohno, et al., 2012 *J Appl Physiol* 112 (10): 1773-1782). Yet, the mechanisms underlying how mechanical strain improves skeletal muscle regeneration at a molecular level remain unclear. Exercise has recently been found to produce a significant increase in circulating exosomes (Fruehbeis, et al., 2015 *J Extracell Vesicles* 4 (1); Whitham, et al., 2018 *Cell Metab* 27 (1): 237-251), suggesting that exosomes may mediate the benefits of exercise on both muscle and bone health.

[0009] miRNA, which is a common non-coding RNA, can target various mRNAs to regulate their physiological activities. Therefore, miRNAs play an important role in various physiological and pathological processes, and so they have been proposed as a powerful tool to treat different diseases efficiently. However, the characteristic of miRNA degradation in vivo limits its further clinical application. Exosomes have the advantage of crossing the biological barrier and achieving long-distance communication with cells, so they are excellent vectors for miRNAs. By studying the biogenesis of exosomes, the way for loading miRNAs, the mechanism of targeting, and disease occurrence and development, it is confirmed that exosomes can enrich specific endogenous miRNAs and regulate a variety of physiological activities, such as promoting cancer cell apoptosis, regulating lipid metabolism and promoting angiogenesis. It is shown that exosomes loaded with miRNAs have good performance in the fields of cancer, neurodegenerative diseases, cardiovascular disease treatment, and regenerative medicine. (Fang, et al., 2022 *Chinese Chem Lett* 4:1693-1704)

BRIEF SUMMARY OF THE DISCLOSURE

[0010] it has previously been demonstrated that in vitro mechanical strain (i.e., ex vivo exercise) and in vivo treadmill exercise can further increase the regenerative capacity of muscle progenitor cells when transplanted into injured skeletal muscle, but the mechanism underlying this observation is unknown. Described herein is the determination of whether exosomes produced by mechanically strained muscle progenitor cells contribute to this increased regenerative capacity. Mechanical strain may alter the secretome of myoblasts to favor the secretion of exosomes with regenerative functions. Ultimately, the instant disclosure guides strategies for the development of exosome therapeutics targeting the age-associated decline in musculoskeletal repair and regeneration.

[0011] Exercise triggers the release of exosomes carrying such metabolic products as, without limitation, microRNA (miRNA), messenger RNA (mRNA), cytokines such as chemokines, interleukins and lymphokines, and other pro-

teins such as growth factors and the like. The thus released exosomes carry a specific miRNA signature. That signature may induce gene expression changes in the subject. The molecular characterization of exercise-induced exosomal miRNAs and their effects may lend to the identification of new therapeutic strategies to alleviate aging-related ailments.

[0012] In one aspect, the disclosure provides a composition comprising exosomes comprising at least one mechanoresponsive miRNA. In one embodiment, the exosomes are derived from mechanosensitive cells. In a further embodiment, the mechanosensitive cells are selected from the group consisting of muscle cells, stem cells (e.g., mesenchymal stem cells, muscle-derived stem cells), muscle fiber (e.g., skeletal muscle fiber), endothelial cells (e.g., blood vessel cells), nerve cells, bone cells (e.g., osteoblasts, osteoclasts, osteocytes), chondrocytes, and cardiomyocytes. In still further embodiments, the cells are from a subject of any age (e.g., embryonic to infant to child to adolescent to young to middle age to old). Thus, for example, the muscle-derived stem cells may be from an elderly subject.

[0013] In one embodiment of a composition according to the disclosure, the exosomes are isolated from a biological sample of a mammalian subject after exercise. In another embodiment, the sample is muscle (e.g., skeletal muscle)—by biopsy, bone marrow, or blood.

[0014] In one embodiment of a composition according to the disclosure, the exosomes are isolated from a cell sample (i.e., *in vitro*) after *ex vivo* exercise. In another embodiment, the *ex vivo* exercise is achieved by a bioreactor creating mechanical strain on cells in the sample.

[0015] In additional embodiments, the exercise is low intensity or high intensity.

[0016] In one embodiment of a composition according to the disclosure, the exosomes are artificially synthesized.

[0017] In another embodiment, a composition according to the disclosure is substantially free of cells.

[0018] In one embodiment of a composition according to the disclosure, the at least one mechanoresponsive miRNA is pro-regenerative. Pro-regenerative, as used herein, refers to promoting proliferation and differentiation. In one embodiment, pro-regenerative refers to promoting proliferation and differentiation of muscle. In another embodiment, pro-regenerative refers to promoting proliferation and differentiation of bone. In another embodiment, some of the miRNAs the exosome comprises are pro-regenerative. In still another embodiment, all of the miRNAs the exosome comprises are pro-regenerative.

[0019] In one embodiment of a composition according to the disclosure, the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-mir-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-miR-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20),

mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22), mmu-miR-7117-3p (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24), mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-7117 (SEQ ID NO: 26), mmu-mir-6905 (SEQ ID NO: 27), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-miR-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), mmu-miR-365-1-5p (SEQ ID NO: 33), mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-mir-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-12203-3p (SEQ ID NO: 48), mmu-miR-363-5p (SEQ ID NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-miR-5617-5p (SEQ ID NO: 52), mmu-mir-7023 (SEQ ID NO: 53), mmu-mir-2139 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-miR-8108 (SEQ ID NO: 58), mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

[0020] In another embodiment, the at least one mechano-responsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-mir-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-miR-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20), mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22), mmu-miR-7117-3p (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24), mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-7117 (SEQ ID NO: 26), mmu-mir-6905 (SEQ ID NO: 27), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-miR-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), and mmu-miR-365-1-5p (SEQ ID NO: 33).

[0021] In still another embodiment, the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-miR-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-12203-3p (SEQ ID NO: 48), mmu-miR-363-5p (SEQ ID NO:

NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-miR-6409 (SEQ ID NO: 52), mmu-miR-5617-5p (SEQ ID NO: 53), mmu-mir-7023 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-miR-8108 (SEQ ID NO: 58), mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

[0022] In further embodiments of a composition according to the disclosure, “at least one” in the context of the miRNAs may mean one, more than one, or all of each of the above lists of miRNAs.

[0023] In one embodiment, a composition according to the disclosure is for use in promoting regeneration in a subject.

[0024] In one embodiment, a composition according to the disclosure is for use in the treatment of a musculoskeletal condition or disorder.

[0025] In one aspect, the disclosure provides a method of preparing a composition comprising exosomes comprising at least one mechanoresponsive miRNA, the method comprising subjecting a mammal to exercise, obtaining a biological sample from the mammal, and isolating the exosomes from the sample. In one embodiment, the sample is muscle (e.g., skeletal muscle)—by biopsy, bone marrow, or blood.

[0026] In another aspect, the disclosure provides a method of preparing a composition comprising exosomes comprising at least one mechanoresponsive miRNA, the method comprising exercising cells (e.g., mechanosensitive cells) ex vivo and isolating the exosomes from the cells. In one embodiment, the ex vivo exercise is achieved by a bioreactor creating mechanical strain on cells in the sample. Exercise, in these embodiments, is mechanical loading that simulates endogenous loading. For muscle cells and the like, mechanical loading by, for example, comprise axial loading and/or uniaxial loading. For chondrocytes and the like, for example, mechanical loading may comprise compressive loading. Mechanical loading may also, in certain embodiments include shear loading.

[0027] In additional embodiments, the exercising is at low intensity or at high intensity.

[0028] In one embodiment of a method according to the disclosure, the at least one mechanoresponsive miRNA is pro-regenerative. In another embodiment, some of the miRNAs the exosome comprises are pro-regenerative. In still another embodiment, all of the miRNAs the exosome comprises are pro-regenerative.

[0029] In one embodiment of a method according to the disclosure, the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-miR-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-miR-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20), mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22),

mmu-miR-7117-3p (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24), mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-7117 (SEQ ID NO: 26), mmu-mir-6905 (SEQ ID NO: 27), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-miR-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), mmu-miR-365-1-5p (SEQ ID NO: 33), mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-mir-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-12203-3p (SEQ ID NO: 48), mmu-miR-363-5p (SEQ ID NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-mir-6409 (SEQ ID NO: 52), mmu-miR-5617-5p (SEQ ID NO: 53), mmu-mir-7023 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-miR-8108 (SEQ ID NO: 58), mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

[0030] In another embodiment, the at least one mechano-responsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-mir-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-mir-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20), mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22), mmu-miR-7117-3p (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24), mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-7117 (SEQ ID NO: 26), mmu-mir-6905 (SEQ ID NO: 27), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-mir-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), and mmu-miR-365-1-5p (SEQ ID NO: 33).

[0031] In still another embodiment, the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-mir-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-363-5p (SEQ ID NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-mir-6409 (SEQ ID NO:

52), mmu-miR-5617-5p (SEQ ID NO: 53), mmu-mir-7023 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-miR-8108 (SEQ ID NO: 58), mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

[0032] In further embodiments of a method according to the disclosure, “at least one” in the context of the miRNAs may mean one, more than one, or all of each of the above lists of miRNAs.

[0033] In one aspect, the disclosure provides a method of promoting regeneration in a subject, comprising administering a composition according to the disclosure to the subject.

[0034] In another aspect, the disclosure provides a method of treating a musculoskeletal condition or disorder in a subject, comprising administering a composition according to the disclosure to the subject.

[0035] In one aspect, the disclosure provides a method of loading an artificially synthesized exosome with at least one mechanoresponsive miRNA. In one embodiment, the exosome is loaded with the at least one mechanoresponsive miRNA using a method selected from the group consisting of active packaging, electroporation, transfecting mechano-sensitive cells, producing hybrid exosome-liposome, and cellular nanoporation.

[0036] Other embodiments will become apparent from a review of the ensuing detailed description.

BRIEF DESCRIPTION OF THE FIGURES

[0037] FIG. 1 shows a FlexCell Bioreactor diagram and mechanical strain regimens. Using the FlexCell system, two mechanical strain regimens were created. Their % elongationxtime wave functions are shown.

[0038] FIGS. 2A to 2I show how mechanical strain influences exosome production. (FIG. 2A) Schematic depicting C2C12 growth following mechanical strain; (FIG. 2B) C2C12 proliferation slows during mechanical strain. Immediately following the mechanical strain regimens, C2C12 cells were collected and counted; (FIG. 2C) C2C12 proliferation increases after mechanical strain. Two-way ANOVA results found cells subjected to the HSSD mechanical strain to be significantly greater than static controls at days 1 and 2, while cells subjected to the LSCL were found to be significantly different at days 1, 2, and 3 ($F(6,45)=10.20$, $n=6/time$, p -values found in Tables 2A and 2B, below); (FIG. 2D-2I) Mechanical strain promotes C2C12 exosome production. Isolated exosome supernatants were subjected to BCA total protein assays, CD81 ELISAs, and flow cytometry to determine protein (FIG. 2D), CD81+ (FIG. 2E) and total exosome (FIG. 2I) concentrations (* $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$). (FIG. 2F) size reference beads. (FIG. 2G) unstained exosomes, (FIG. 2H) stained exosomes.

[0039] FIG. 3 shows qNano results showing that exosome isolates fall within the 50~ 150 nm particle size range.

[0040] FIGS. 4A-4I show that exosomes from mechanically strained C2C12 cells improve proliferation and differentiation. (FIG. 4A) Schematic depicting naïve C2C12 cell treatment with exosomes; FIGS. 4B and 4C show that exosomes from mechanically strained cells improve C2C12 proliferation (FIG. 4B in graph form, FIG. 4C in quantitative form). Two-way ANOVA results found cells treated with LSCL exosomes to be significantly greater than static at day 3 and 5 ($F(6, 40)=12.79$, $n=6/time$, p -values found in FIG.

[0043] FIGS. 4D-4I show that exosomes from mechanically strained cells improve myotube area (FIG. 4D) and myotube nuclear fusion index (FIG. 4E); one-way ANOVAs were performed for all other analysis (* $p<0.05$, ** $p<0.01$. *** $p<0.001$, **** $p<0.0001$). Staining shown in (FIG. 4F)-exosomes; (FIG. 4G)+static exosomes; (FIG. 4H)+HSSD exosomes; (FIG. 4I)+LSDL exosomes.

[0041] FIGS. 5A-5C show (FIG. 5A) that mechanically stimulated cells proliferate faster than static controls; (FIG. 5B) P-values for all comparisons; and (FIG. 5C) 2-way ANOVA with Tukey's HSD results.

[0042] FIGS. 6A-6C show (FIG. 6A) that cells treated with exosomes from mechanically strained cells proliferate faster; (FIG. 6B) P-values for all comparisons; (FIG. 6C) 2-way ANOVA with Tukey's HSD results.

[0043] FIGS. 7A-7E show that mechanical strain produces unique and differential miRNA within exosomes. (FIG. 7A) the total number of mapped miRNAs per group is listed to the outside, while unique and shared miRNAs are represented within each circle; (FIG. 7B) the heatmap depicts all significant miRNA for each comparison; (FIGS. 7C-7E) volcano plots represent differentially regulated miRNA for each comparison, (FIG. 7C) HSSD vs. static, (FIG. 7D) LSDL vs. static, (FIG. 7E) HSSD vs. LSDL.

[0044] FIG. 8 shows Table 2A, which lists the enriched Gene Ontology terms for HSSD vs. static.

[0045] FIGS. 9A-9C show miRNA gene ontology. (FIG. 9A) Terminal nodes of enriched Gene Ontology (GO) terms for HSSD vs. static and HSSD vs. LSDL statistically significant miRNA comparisons; blue bars=FDR <0.05 and gray bars=FDR >0.01 ; (FIG. 9B) GO term categories for the HSSD vs. static comparison; (FIG. 9C) GO term categories for the HSSD vs. LSDL comparison.

DETAILED DESCRIPTION

[0046] Before the present compositions and methods are described, it is to be understood that this disclosure is not limited to particular compositions and methods, and experimental conditions described, as such compositions and methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0047] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference in their entirety.

Definitions

[0048] The term "mechanoresponsive", as used herein, refers to miRNAs that are upregulated and downregulated following mechanical stimuli. The term also refers to miRNAs that are up- or down-regulated in mechanosensitive cells upon exercise.

[0049] The term "mechanical stimuli", as used herein, refers to tension, compression, and/or shear.

[0050] The term "mechanosensitive", as used herein, refers to cells that respond to, or that are known to respond to, various mechanical stimuli. Mechanosensitive cells may include, in various embodiments, isolated muscle cells (e.g., myocytes), stem cells (e.g., mesenchymal stem cells, muscle-derived stem cells, satellite cells), skeletal muscle fiber (e.g., myofibrils), endothelial cells (e.g., blood vessel cells), nerve cells, bone cells (e.g., osteoblasts, osteoclasts, osteocytes), chondrocytes, and cardiomyocytes.

[0051] The term "substantially free", as used herein, refers, in the context of a composition, to a composition being free of cells or other stated substance (other than exosomes), a composition wherein the cells or other stated substance is/are undetectable, or a composition including less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, or less than about 10% cells or other stated substance. For example, the compositions are essentially free of cellular debris, apoptotic bodies, and microvesicles having a diameter less than about 20 nm or greater than about 140 nm.

[0052] Furthermore, the term "substantially free", as used herein, refers, in the context of a composition, to a composition being substantially free of cells, platelets, polypeptides, minerals, blood borne compounds or chemicals, virus, bacteria, fungus, yeast, pathogens, toxins, parasites, and/or the like.

[0053] The term "about", as used herein with respect to any given value, refers to a deviation from that value of up to 10%, either up to 10% greater, or up to 10% less. In additional embodiments, the term refers to a value $\pm 5\%$ of that value, $\pm 4\%$ of that value, $\pm 3\%$ of that value, $\pm 2\%$ of that value, or $\pm 1\%$ of that value.

[0054] Compositions according to the disclosure are, in some embodiments, administered to a subject in a therapeutically effective amount. The term "therapeutically effective amount", as used herein, refers to an amount that produces the desired effect for which it is administered. The exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques.

[0055] As used herein, the term "subject" refers to an animal, preferably a mammal, more preferably a human. As such, subjects of the disclosure may include, but are not limited to, humans and other primates, such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats, and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats, and guinea pigs; birds, including domestic, wild, and game birds such as chickens, turkeys, and other gallinaceous birds, ducks, geese, and the like. In certain embodiments, the subject is a human.

[0056] As used herein, the terms "treat", "treating", or "treatment" refer to the healing of a bone fracture in a subject in need thereof. The terms include healing of the actual fracture and may additionally or alternatively include ameliorating a symptom associated with the bone fracture, for example, pain, inflammation, reduced mobility, etc.

Exosomes

[0057] Exosomes are nano-sized membrane-bound/membrane-encapsulated vesicles that are released from many cell types into the extracellular space. They are widely distributed in various body fluids. Exosomes are typically about 40

nm to about 100 nm in diameter, but they may have a diameter of about 40 nm to about 140 nm. In one embodiment, exosomes according to the disclosure are about 100 nm in diameter. Exosomes can generally be isolated from, without limitation, whole blood, serum, plasma, urine, saliva, breast milk, cerebrospinal fluid, amniotic fluid, ascitic fluid, and bone marrow of a mammal, as well as from cultured mammalian cells (e.g., immature dendritic cells (wild-type or immortalized), induced and non-induced pluripotent stem cells, fibroblasts, platelets, immune cells, reticulocytes, tumor cells, mesenchymal stem cells, satellite cells, hematopoietic stem cells, pancreatic stem cells, white and beige pre-adipocytes, and the like. However, in embodiments of the compositions according to the instant disclosure, the exosomes are derived from mechanosensitive cells selected from the group consisting of muscle cells, stem cells (e.g., mesenchymal stem cells, muscle-derived stem cells), muscle fiber (e.g., skeletal muscle fiber), endothelial cells (e.g., blood vessel cells), nerve cells, bone cells (e.g., osteoblasts, osteoclasts, osteocytes), chondrocytes, cardiomyocytes, and any other mechanosensitive cells. Cultured cell samples are, in a further embodiment, cultured in cell-appropriate culture media, using exosome-free serum.

[0058] Exosomes are advantageous vehicles for miRNAs due to lack of immunoreactivity/immunogenicity and due to their good storage stability. Their lack of immunoreactivity/immunogenicity may make them safe for autologous, allogenic, and xenogenic use. These traits provide exosomes regulatory (FDA approval path) and manufacturing advantages. Finally, the lipid-bilayer nature of exosomes allows for efficient uptake of exosome cargo into recipient cells.

[0059] Because exosomes are neither immunoreactive or immunogenic, they could, in one embodiment, hail from an autologous donor that is used for all treatments (e.g., universal donor). For example, a cell line can, in one embodiment, be created from an ideal donor and then maintained for ex vivo exercise and exosome isolation over time.

[0060] Exosomes can be isolated from a sample using standard, state-of-the-art methods including, but not limited to, commercially available kits, PEG-based methods, ultrafiltration (for example, ultrafiltration using a tangential fluid filtration (TFF) system (El-Baradie, et al., 2020 *Frontiers in Cell Dev Biol* 8 (181, pp 1-12), and/or ultracentrifugation/density gradient methods.

[0061] Exosomes can be isolated, in one embodiment, by taking advantage of known specific surface markers not present in other vesicles, for example, surface markers such as tetraspanins, e.g., CD9, CD37, CD44, CD53, CD63, CD81, CD82, and CD151.

Artificial Exosomes

[0062] In certain embodiments of the compositions and methods according to the disclosure, the exosomes are artificially synthesized as engineered lipid nanoparticles. The artificial exosomes of certain compositions and methods of the disclosure are engineered for stability, circulating ability (long $t_{1/2}$), targeting ability, and biocompatibility (i.e., minimized cytotoxicity and immunogenicity). In one embodiment, an artificial exosome is synthesized using standard, state-of-the-art nanofluidic technology. A nanofluidic device is used to make uniform lipid nanoparticles. The composition of lipid nanoparticles is then engineered to be biocompatible (e.g., non-inflammatory) and to encapsulate

mechanoresponsive miRNAs. The lipid composition is based on the state of the art of the field.

[0063] In one embodiment, artificial exosomes according to the disclosure are engineered to be about 100 nm in diameter. In another embodiment, a composition according to the disclosure comprises exosomes that are substantially consistent in size.

miRNAs

[0064] mRNAs and microRNAs (miRNAs) have been identified in exosomes, which can be taken up by recipient cells and subsequently modulate the same. An active sorting mechanism of exosomal miRNAs may be indicated, since the miRNA profiles of exosomes may differ from those of the parent cells.

[0065] microRNAs are small, single-stranded non-coding ribonucleic acid molecules about 18 to about 28 nucleotides long, with an average length of about 22 nucleotides. They regulate gene expression at the posttranscriptional level by either changing mRNA stability and degrading them or by inhibiting protein translation (Fabian, et al., 2010 *Annu Rev Biochem* 79:351-379). miRNAs thus modulate the activity of numerous target genes and are implicated in fundamental physiological processes. Due to their robust biological output, these regulatory RNAs (~22 bp) may offer a relatively simple, inexpensive, and scalable way to guide cellular activities.

[0066] Precursor miRNAs (pre-miRs or "mirs") are processed by ribonuclease III enzymes, for example, Dicer or Drosha, into mature miRNAs (or "miRs") after a series of processing steps.

[0067] A subset of exosomal miRNAs increases in abundance following exercise, suggesting an exercise-induced release of exosomes enriched in specific miRNAs. The exosomes disclosed herein comprise at least one mechanoresponsive miRNA. The murine miRNAs are listed in Table 1, further below. In certain embodiments, the exosomes can comprise 1, more than one, or all of the human equivalents of the mechanoresponsive miRNAs listed in Table 1 under "HSSD" (high strain short duration). In other embodiments, the exosomes can comprise 1, more than one, or all of the human equivalents of the mechanoresponsive miRNAs listed in Table 1 under "LSLD" (low strain long duration). And in still other embodiments, the exosomes can comprise 1 each or more than one each of the human equivalents of the mechanoresponsive miRNAs listed in Table 1 under "HSSD" and "LSLD". Three human equivalent miRNAs are disclosed herein (but are not included in Table 1): hsa-miR-124-5p (SEQ ID NO: 62), hsa-miR-491-3p (SEQ ID NO: 63), and hsa-miR-128-2-5p (SEQ ID NO: 64).

[0068] In some embodiments, mechanoresponsive miRNAs can be identified and/or characterized using bioinformatics and/or an assay selected from the group consisting of qPCR, miRNA array, and RNA-seq.

Exercise

[0069] Exercise is generally defined as an activity requiring physical effort. It may be carried out to sustain or improve health and fitness. The term "exercise" may encompass endurance exercise, high-intensity interval training, resistance exercise, and the like, as well as combinations thereof. In one embodiment, a mammal exercises, for example, on a treadmill.

[0070] In certain embodiments of compositions and methods according to the disclosure, exosomes are isolated from

a cell sample (i.e., *in vitro*) after *ex vivo* exercise. This *ex vivo* exercise is achieved by a bioreactor creating mechanical tension on cells in the sample. The mechanical bioreactor, in these embodiments, simulates endogenous exercise. For muscle cells or fibers and the like, mechanical loading may, for example, comprise axial loading and/or uniaxial tension. For chondrocytes and the like, for example, mechanical loading may comprise compressive and shear loading.

[0071] Exercise is, in some embodiments, referred to herein as low intensity or high intensity. Low intensity corresponds to low strain for long duration (LSDL), while high intensity corresponds to high strain for short duration (HSSD). An LSDL regimen, in one embodiment, comprises subjecting cells to 0-15% strain (% elongation) at 0.5 Hz for 24 hrs. an HSSD regimen, in one embodiment, comprises subjecting cells to 12-22% strain (% elongation) at 1 Hz for 10 minutes, followed by 50 minutes rest at 0% strain, for 24 hours. These regimens are to be seen as representative, but not limiting, of low intensity and high intensity exercise. The bioreactor used may, for example, define or limit the low vs. high intensity training exercise. Thus, a different bioreactor may allow for different intensity parameters; these parameters are likewise contemplated for the compositions and methods according to the disclosure.

[0072] The biological sample or cell sample is obtained immediately after (within 60 seconds, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 1 hour, within 2 hours, within 3 hours, or within 4 hours of) completion of exercise regimen, and the exosomes are subsequently isolated therefrom.

Compositions

[0073] Exosomes obtained according to the disclosure may be formulated for therapeutic use by combination with a pharmaceutically or physiologically acceptable carrier. The terms “pharmaceutically acceptable” or “physiologically acceptable”, as used herein, refer to carriers that are acceptable for use in the pharmaceutical and veterinary arts. The carrier may be selected with a view to its intended use and/or its intended administration method.

[0074] In one embodiment, the exosomes are formulated as a suspension in a medical-grade, physiologically acceptable carrier, such as an aqueous solution in sterile and pyrogen-free form, optionally, buffered or made isotonic. The carrier may be distilled water (DNase- and RNase-free), a carbohydrate-containing solution (e.g., sucrose or dextrose) or a saline solution comprising sodium chloride and optionally buffered. Suitable saline solutions may include varying concentrations of sodium chloride, for example, normal saline (0.9%), half-normal saline (0.45%), quarter-normal saline (0.22%), and solutions comprising greater amounts of sodium chloride (e.g., 3%-7%, or greater). Saline solutions may optionally include additional components, e.g., carbohydrates such as dextrose and the like. Examples of saline solutions including additional components, include Ringer’s solution, e.g., lactated or acetated Ringer’s solution, phosphate buffered saline (PBS), TRIS (hydroxymethyl) aminomethane hydroxymethyl) aminomethane)-buffered saline (TBS), Hank’s balanced salt solution (HBSS), Earle’s balanced solution (EBSS), standard saline citrate (SSC), HEPES-buffered saline (HBS), and Gey’s balanced salt solution (GBSS).

[0075] (Pharmaceutical) compositions in accordance with the disclosure are administered with suitable excipients, and/or other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington’s Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTINTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell, et al., “Compendium of excipients for parenteral formulations”, PDA (1998), *J Pharm Sci Technol* 52:238-311.

[0076] In certain embodiments, the excipient is simply water, and in one embodiment, pharmaceutical grade water. In other embodiments, the excipient is a buffer, and in one embodiment, the buffer is pharmaceutically acceptable. Buffers may also include, without limitation, saline, glycine, histidine, glutamate, succinate, phosphate, acetate, aspartate, or combinations of any two or more buffers.

[0077] In other embodiments, a hydrogel carrier is included in the composition. In additional embodiments, the hydrogel is viscous, yet still flowable, and in other embodiments, the hydrogel is solid, semi-solid, gelatinous or of any density in between. Accordingly, in various embodiments and without limitation, the hydrogel is natural a substance comprised of collagen, gelatin, gluten, elastin, albumin, chitin, hyaluronic acid, cellulose, dextran, pectin, heparin, agarose, fibrin, alginate, carboxymethylcellulose, Matrige™ (a hydrogel formed by a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma), hydrogel organogel, or mixtures and/or combinations thereof.

[0078] In another embodiment, microparticles are synthesized from one or more polymers, one or more copolymers, one or more block polymers (including di-block polymers, tri-block polymers, and/or higher multi-block polymers), as well as combinations thereof. Useful polymers include, but are not limited to, polylactic acid (PLA), polyglycolic acid (PGA), poly(epsilon-caprolactone) (PCL), poly(ethylene glycol) diacrylate (PEGDA), poly(ethylene glycol) dimethacrylate (PEGDMA), SU-8, poly(methyl methacrylate), poly(lactide-co-glycolide), poly-caprolactone, and elatin/caprolactone, collagen-GAG, collagen, fibrin, poly(anhydrides), poly(hydroxy acids), poly(ortho esters), poly(propylfumerates), polyamides, polyamino acids, polyacetals, biodegradable polycyanoacrylates, biodegradable polyurethanes and polysaccharides, polypyrrole, polyanilines, poly-thiophene, polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly(ethylene vinyl acetate), polypropylene, polyethylene, polycarbonates, poly(ethylene oxide), polydioxanone, “pseudo-polyamino acid” polymer based on tyrosine, tyrosine-derived polycarbonate poly(DTE-co-DT carbonate), tyrosine-derived polyarylate, poly-anhydride, trimethylene carbonate, poly(.beta.-hydroxybutyrate), poly(g-ethyl glutamate), poly(DTH iminocarbonate), poly(bisphenol A iminocarbonate), poly(ortho ester), polycyanoacrylate, and polyphosphazene, poly(lactide-co-glycolide) (PLGA), poly(DL-lactide-co-epsilon-caprolactone) (DLPLCL), a modified polysaccharide

(cellulose, chitin, dextran) a modified protein, casein- and soy-based biodegradable thermoplastics, collagen, polyhydroxybutyrate (PHB), multiblock copolymers of poly(ethylene oxide) (PEO) and poly(butylene terephthalate) (PBT), polyrotaxanes. In other embodiments, the microparticles are formed from one or more phospholipids. 2-methacryloyloxyethyl phosphorylcholine (MPC), one or more cationic polymers (poly(a-[4-aminobutyyl]-L-glycolic acid), or one or more silicone-urethane copolymers. In still other embodiments, microparticles are formed from co-polymers of any of the above, mixtures of the above, and/or adducts of the above. Again, the worker of ordinary skill in the art will appreciate that any pharmaceutical grade matrix is amenable for use in a composition of the disclosure.

[0079] Injectable compositions may include dosage forms for intravenous, subcutaneous, percutaneous, intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by methods publicly known.

[0080] Compositions according to the disclosure are, in one embodiment, stored in liquid form. In another embodiment, compositions according to the disclosure are stored in lyophilized form. In still another embodiment, compositions according to the disclosure can be freeze-dried with lyoprotectants, for example PVP+trehalose (El-Baradie, et al., 2020 *Frontiers in Cell Dev Biol* 8 (181, pp 1-12)). In some embodiments, liquid compositions according to the disclosure are stably stored as at -80° C. for at least about 6 months. In some embodiments, liquid compositions according to the disclosure are stably stored at -20° C. for at least about 3 months and up to about 6 months. In other embodiments, lyophilized compositions according to the disclosure are stably stored at room temperature.

Administration

[0081] Certain aspects of the present disclosure include administering a composition comprising exosomes comprising mechanoresponsive miRNAs to a subject. In practicing the methods and uses according to certain embodiments of the disclosure, a composition comprising exosomes comprising mechanoresponsive miRNAs is administered to a subject.

[0082] In certain embodiments, a composition according to the disclosure is administered locally. The term "locally", as used herein, may refer to an injury or surgery site, or adjacent to an injury or surgery site.

[0083] Modes of administration may include, but are not limited to injection (e.g., percutaneously, subcutaneously, intravenously, or intramuscularly, intrathecally). In certain embodiments, the mode of administration is surgical implantation (for example, of a hydrogel/matrix as described herein).

[0084] A composition according to the disclosure can, in certain embodiments, be delivered subcutaneously or percutaneously with a standard needle and syringe. In addition, a pen delivery device may, in one embodiment, be employed to administer a composition of the present disclosure.

[0085] In certain embodiments, a composition according to the disclosure can be delivered in a controlled release system. In one embodiment, a pump may be used. In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose.

[0086] In certain embodiments, the frequency and the duration of the administration can be adjusted. In certain embodiments, the composition can be administered as a single dose of exosomes. In other embodiments, the composition can be administered as an initial dose, followed by administration of a second or a plurality of subsequent doses of the exosomes comprising at least one mechanoresponsive miRNA in an amount that can be approximately the same or less than that of the initial dose, wherein the subsequent doses are separated by at least one week, at least 2 weeks, at least 3 weeks, at least one month, at least two months, at least three months, or longer, based on a lack of adequate progression of desired effect. In certain embodiments, a lack of adequate progression of desired effect comprises no reduction in pain, minimal reduction in pain, no or minimal increase in stability, no or minimal increase in mobility, no or low (bone) mineralization on X-ray, no or low reduction in inflammation, and/or no or low increase in strength. A clinician would be able to change the frequency and duration of treatment on a per patient basis based on their diagnosis and unique condition.

Uses

[0087] Compositions according to the disclosure are, in some embodiments, for use in promoting regeneration in a subject. Promoting regeneration comprises promoting proliferation and/or cellular differentiation. In a further embodiment, compositions according to the disclosure are for use in promoting muscle repair and/or promoting muscle regeneration. In still a further embodiment, compositions according to the disclosure are for use in promoting bone repair. In one embodiment, compositions according to the disclosure are for use in replacing orthobiologics in any situation in which orthobiologics are being used. In another embodiment, compositions according to the disclosure are for use in replacing orthobiologics (for example, platelet-rich plasma (PRP), bone marrow aspirate) in the treatment of a musculoskeletal condition or disorder. In yet another embodiment, compositions according to the disclosure are for use in orthopedic recovery post-surgery. In a further embodiment, compositions according to the disclosure are for use in reducing a pro-inflammatory state. In still a further embodiment, compositions according to the disclosure are for use in improving the age state of a person through cellular rejuvenation.

[0088] Compositions according to the disclosure are, in further embodiments, for use in the treatment of a musculoskeletal condition or disorder. In specific embodiments, the musculoskeletal condition or disorder is selected from the group consisting of, but not limited to, atrophy, sarcopenia, osteoarthritis, osteoporosis, injury, and age-related frailty.

[0089] In one embodiment, a subject may be unable to exercise as required or to exercise at all; a (mechanosensitive) cell sample could be obtained from the patient and exercised *ex vivo*, exosomes could be isolated from the cells in the sample, and a composition comprising the isolated exosomes could then be administered to the subject. In another embodiment, the cell sample hails from a universal autologous donor.

[0090] In another embodiment, a composition comprising mechanoresponsive miRNAs as disclosed herein is characterized with a view to personalizing an exercise program for a subject to maximize the promotion of regeneration in the

subject. In such an embodiment, the injury or disease is characterized, and a composition is prepared comprising exosomes that comprise the mechanoresponsive miRNAs that affect the regulatory processes of relevance to the subject. Alternatively, mechanoresponsive miRNAs are identified and characterized in exosomes released after varying types and intensities of exercise. An exercise regimen is then tailored to a subject based on the mechanoresponsive miRNAs they “need” (i.e., those mechanoresponsive miRNAs that affect the regulatory processes of relevance to the subject).

Combination Therapies

[0091] In some embodiments, a composition according to the disclosure is administered to a subject in combination with another therapeutic agent or therapy.

[0092] As used herein, the term “in combination with” means that at least one additional therapeutic agent/therapy may be administered prior to, concurrent with, or after the administration of the composition comprising exosomes comprising mechanoresponsive miRNAs.

EXAMPLES

[0093] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the disclosure, and are not intended to limit the scope of what the inventors regard as their disclosure. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, room temperature is about 25° C., and pressure is at or near atmospheric.

Example 1: Exosome Preparation and miRNA Characterization

1.1 Methods, Cell Culture

[0094] C2C12 myoblasts (ATCC, catalog #CRL-1722) were cultured in growth media containing Dulbecco’s Modified Eagle Medium (DMEM; Gibco, catalog #11995040), 10% Fetal Bovine Serum (FBS; Gibco, catalog #10437028), and 1% penicillin/streptomycin (P/S; Gibco, catalog #15140148) at 37° C. in humidified air containing 5% CO₂. Cells were maintained in tissue culture treated T75 flasks (Corning, catalog #10-126-11) and not passaged more than eight times.

1.2 Methods, Mechanical Strain

[0095] Using a commercially available bioreactor (Flex-Cell International, catalog #FX-5000TT), 100,000 C2C12 cells per well were plated onto 6-well BioFlex culture plates (FlexCell International, catalog #BF-3001U). Two cyclic tension regimens were created. The first regimen subjected cells to a low strain for a long duration (LSD) of 0-15% strain at 0.5 Hz for 24 hours. The second subjected cells to a high strain for a short duration (HSSD) of 12-22% strain at 1 Hz for 10 minutes followed by 50 minutes of rest at 0% strain for 24 hours. Static (“unexercised”) groups were plated in parallel to the LSD and HSSD (“exercised”) groups (FIG. 1).

1.3 Methods, Exosome Isolation

[0096] Media containing exosome-depleted FBS (Gibco, catalog #A2720803) was added and incubated with the cells for the 24-hour “exercise” regimen. The media was collected and centrifuged at 1,500×g for 10 minutes followed by a second centrifugation at 3,000×g for 10 minutes before being centrifuged at 4,000×g for 10 minutes using 100 kDa concentrating columns (Amicon, catalog #UFC910024). The concentrated media was then incubated with the Invitrogen Total Exosome Isolation Reagent (Invitrogen, catalog #4478359) overnight at 4° C. before being centrifuged at 10,000×g for 1 hour at 4° C. Exosome pellets were resuspended in 500 μL of 1×0.02 μm filtered PBS and stored at -80° C.

1.4 Methods, C2C12 Post-Exercise Regimen Proliferation

[0097] Following the mechanical strain regimens, the cells were collected, counted, and 5,000 C2C12 cells from each group were replated into separate wells of a 24-well plate (Genesee, catalog #25-107). After adhering overnight, the cells were treated with the PrestoBlue Cell Viability Reagent according to the manufacturer’s instructions at days 1, 2, and 3 (FIG. 2A).

1.5 Methods, Exosome and Exosome Protein Content Quantification

[0098] Two methods were used to quantify exosome numbers in the conditioned media from each experimental condition. Exosome tetraspanin marker CD81 was quantified using System Bioscience’s ExoELISA-ULTRA Complete CD81 Detection according to the manufacturer’s instructions (SBI, catalog #EXEL-ULTRA-CD81-1). Aggregate exosome concentrations were quantified using System Biosciences ExoFlow-ONE EV Labeling Kit (SBI, catalog #EXOF400A-1) on the Cytek Northern Lights flow cytometer (Cylek, catalog #NL-3000). Methodologies followed SBI’s staining protocol and a previously published protocol for optimized quantification using the Cytek Northern Lights instrument (Coughlan, et al., 2020 *Curr Protoc Cell Biol* 88 (1). <https://pubmed.ncbi.nlm.nih.gov/32633898/>). To ensure accurate measurements were made, a serial dilution of aggregate exosome sample was made and quantified for each run. Sample results were only quantified if the run’s corresponding serial dilution curve had an R² exceeding 0.9. Exosome protein concentrations from each group were determined using the Pierce Microplate Bicinchoninic Acid Assay according to manufacturer’s instructions (BCA; Thermo, catalog #23252). The Izon qNano Gold TRPS instrument was also used to confirm isolation of exosome sized extracellular vesicles (FIG. 3).

1.6 Methods, Naïve C2C12 Treatment with Exosomes

[0099] Using normal growth media 5,000 C2C12 cells were plated into separate wells of a 24-well plate. After adhering overnight, the cells were washed and treated with PBS or 10 μg/ml of static, HSSD, or LSD exosomes on days 1 and 3. Growth media containing exosome-depleted FBS was used for all treatments. Following manufacturer’s instruction, the PrestoBlue Cell Viability Reagent was used

to determine cell proliferation at day 1 (prior to treatment), day 3 (48 hours after the first treatment), and day 5 (48 hours after the second treatment).

[0100] At day 5, the cells were treated with differentiation media supplemented with PBS or 10 µg/mL of static, HSSD, or LSCL exosomes. C2C12 differentiation media contained 2% exosome-depleted FBS. C2C12 cells were subsequently cultured for 3 days (FIG. 4A).

1.7 Methods, Immunofluorescence Staining

[0101] Cells were washed with PBS, fixed using cold 4% PFA (Alfa Aesar, Catalog #J19943K2) for 15 minutes, and washed three more times. The cells were then blocked using 10% donkey serum (DS; Jackson Immuno, catalog #017000121) and 0.3% Triton X-100 (Fisher, catalog #BP151-500) in PBS for 1 hour followed by a 3-hour incubation at room temperature with the myosin heavy chain antibody (MHC: R&D Systems, Catalog #MAB4470). 10 µg/mL of MHC was suspended in dilution buffer containing 1×PBS with 1% DS, 1% bovine serum albumin (BSA; Sigma, catalog #A9647-100G), and 0.3% Triton X-100. The cells were then washed three times using 1×PBS with 0.1% BSA and then incubated with 1:400 diluted Alexa Flour 594 (Invitrogen, catalog #A21203) for 1 hour at room temperature. The cells were washed three more times and incubated with 1 µg/ml of DAPI (Sigma, catalog #D9542-10 MG) for 10 minutes before being washed.

1.8 Methods, Myotube Quantification

[0102] Cells were imaged using the Nikon Eclipse Ti-E microscope. Three wells were imaged per group and within each well sixteen 10× images were taken in a 4×4 automated grid pattern. The opensource MyoCount program was then used to process the images and determine the myotube area and the nuclear fusion index of each image (Murphy, et al., 2019 Wellcome Open Res 4 <https://pubmed.ncbi.nlm.nih.gov/30906880/>).

1.9 Methods, miRNA Next Generation Sequencing

[0103] Three exosome replicates from each group (static, HSSD, and LSCL) were sent to System Biosciences for exosomal RNA sequencing. The miRNA samples were isolated and sequenced using SBI's protocols and, upon sequencing, the results were analyzed using the Exosome Small RNA-seq Analysis Kit on the cloud-based Maverix Analytic Platform. Data analysis was visualized and downloaded using the University of California Santa Cruz Banana Slug Analytics Platform.

1.10 Methods, miRNA Gene Ontology

[0104] Significantly up-/down-regulated miRNAs were determined by Banana Slug Genomics and analyzed independently for gene targets using mirDB (Chen and Wang, 2020 *Nucleic Acids Res* 48, Liu and Wang, 2019 *Genome Biol* 20 (1)). A threshold of 95% target predication score was used for downstream analysis of miRNA gene targets. Gene targets with a target prediction score of greater than or equal to 95% were then analyzed for enriched Gene Ontology (GO) terms using GOrilla with *Mus musculus* as the target organism (Eden, et al., 2009 *BMC Bioinformatics* 10 (1), Eden, et al., 2007 *PLOS Comput Biol* 3 (3)). Gene targets were analyzed as two unranked lists of gene sets, with the *Mus musculus* proteome as the background gene set.

Enriched GO terms are shown in Tables 2A (FIG. 8) and 2B, below. A terminal node analysis was then performed on the enriched GO terms in R Studio using the Bioconductor GO.db package, and the most specific enriched GO terms (terminal nodes) with FDR<0.1 were reported.

[0105] To categorize the enriched GO terms, four reviewers were prompted with seven umbrella categories (development, signaling, metabolism, muscle, neural, inflammation, and transcriptional regulation) and asked to assign one category to each GO term. The reviewers were blinded to one another's responses and the category selected by the majority of the reviewers was assigned to each GO term (Tables 3A and 3B, below).

1.11 Methods, Statistics

[0106] All statistical comparisons and figures were generated using the PRISM 9 analysis software. All mean values and standard deviations were determined from at least three replicates. Where present, individual data points represent one replicate. One-way ANOVAs were completed to test for significant difference between multiple comparisons, while two-way ANOVAs were run to compare multiple groups over time. Tukey's honestly significant difference (HSD) post-hoc testing was completed in both scenarios. Values with a p<0.05 were considered to be statistically significant.

Results

Mechanical Strain Influences Exosome Production

[0107] Following 24 hours of mechanical strain (FIG. 1), C2C12 cell counts from both HSSD and LSCL groups were significantly lower than the static group at the completion of their respective regimens (FIG. 2B). This led to the question of whether mechanical strain impacted C2C12 proliferation. Using the PrestoBlue Cell Viability Reagent to colorimetrically determine the relative number of cells for 3 days following the completion of loading and replating at equal densities, cell number was found to be different in both a time and group component with a two-way ANOVA analysis ($F_{6,45}=10.20$, (FIG. 2C), time and group comparisons found in FIG. 6). With respect to the different loading groups, after replating at equal densities, cells from the LSCL regimen were increased when compared to the static at days 1, 2, and 3 ($p<0.0001$, $p<0.0001$, and $p<0.0011$, respectively). Similarly, the cell counts subjected to the HSSD regimen were also higher than the static at days 1 and 2 ($p=0.0024$ and $p<0.0001$, respectively). When comparing the LSCL and HSSD groups, it was found that the LSCL cell count was only greater at day 1 ($p<0.0001$). Within each group, cell populations were significantly greater at each day when compared to the previous day ($p<0.0001$).

[0108] After observing the increase in proliferation following mechanical strain, the isolated exosomes within each group were characterized to determine if mechanical strain impacted exosome production. By using a bicinchoninic acid (BCA) assay, no significant difference was observed in the protein concentration within the exosomes of each group following the mechanical strain regimens (FIG. 2D). However, the concentration of CD81+ exosomes were increased by both HSSD and LSCL regimens when compared to static conditions. While the HSSD conditions did not result in a significantly higher CD81+ exosome production (FIG. 2E, $p=0.1468$), LSCL conditions resulted in significantly

increased exosomes relative to static ($p<0.0001$) and HSSD conditions ($p=0.031$, FIG. 2E). It is, thus, indicated that exercise causes not only cells to proliferate, but also causes an increased production of exosomes.

[0109] Using flow cytometry-based exosome quantification, the finding that exosome concentrations were increased was confirmed with a secondary measurement (FIG. 2F-2H). It is similarly shown herein that both HSSD and LSLL mechanical strain regimens resulted in the production of significantly more exosomes when compared to the static conditions (FIG. 2I, HSSD vs static $p=0.0321$, LSLL vs static $p<0.0001$, HSSD vs LSLL $p=0.0351$). Of note the two methods of exosome quantification were used to complement each other, with the difference in y-axis range when comparing FIGS. 2E and 2I likely due to the loss in single vesicle resolution through the flow cytometer.

Exosomes from Mechanically Strained C2C12 Cells Improve Proliferation and Differentiation

[0110] Following quantification, exosome suspensions from each group were added to naïve C2C12 cells. This resulted in a greater cell count for all groups treated with exosomes when compared to untreated cells (-Exo) (FIG. 4B; F6,40=12.79, time and group comparisons found in FIG. 6). Following treatment with exosomes from the HSSD, a significant increase was observed in cell count compared to the untreated cells at days 3 and 5 ($p=0.0004$ and $p=0.0004$, respectively). Exosomes from the LSLL induced an even greater change, producing a significant difference between the LSLL and untreated cells at days 3 and 5 ($p=0.0027$ and $p=0.0012$, respectively). Exosomes isolated from the static group elicited no significant increase in cell count when compared to the untreated cells. When comparing the static group against HSSD and LSLL, no significant increase in cell count was found after treatment with HSSD exosomes; however, cells treated with LSLL exosomes were significantly more abundant at days 3 and 5 ($p=0.0059$ and $p=0.0411$, respectively). Lastly, cell count was significantly increased in time ($p<0.0001$) resulting in an improved growth rate for all cells treated with exosomes. The LSLL exosomes were found to be particularly effective imparting a 1.827-fold increase in growth rate while static and HSSD exosomes imparted a 0.366- and 1.018-fold increase, respectively (FIG. 4C).

[0111] Following proliferation, the exosome's effects on myogenic differentiation were investigated. All exosome suspensions resulted in greater myotube area and nuclear fusion indexes compared to untreated cells. The myotube area and nuclear fusion index for myotubes containing greater than 3 nuclei were significantly higher in exosomes from LSLL loading programs (FIGS. 4D-4I; $p=0.0039$ and $p=0.0484$, respectively).

Mechanical Strain Produces Unique and Differential miRNA within Exosomes

[0112] It was investigated whether differential expression of miRNA cargo within the exosomes from mechanically strained C2C12 cells might contribute to the observed functional changes in proliferation and myogenesis. miRNA sequencing results revealed that 553 precursor and mature miRNA strands were expressed across exosomes from all groups with both unique and overlapping miRNA content (FIG. 7A, Table 1, below). The static group contained the most overall identifiable miRNA (468), 41 more than LSLL (427) and 95 more than HSSD (373). 264 of the miRNAs were found across all groups, allowing focus upon a smaller

subset of the uniquely expressed miRNAs. The static group had the highest number of unique miRNA (41), while LSLL and HSSD exosomes carried 33 and 28 unique miRNA, respectively. Static and LSLL exosomes had 106 shared miRNA, while static and HSSD shared 57 and LSLL and HSSD shared 24.

TABLE 1

All Mapped miRNA by Group		
HSSD	LSLL	SEQ ID NO
	mmu-mir-344b	1
	mmu-miR-3060-5p	2
	mmu-miR-344b-3p	3
mmu-mir-6378		34
mmu-miR-6378	mmu-mir-12184	35
	mmu-mir-293	4
	mmu-miR-293-3p	5
	mmu-mir-804	6
mmu-miR-6403		7
mmu-miR-7023-5p		36
mmu-mir-6539		37
mmu-miR-1929-5p		38
	mmu-miR-496a-3p	39
	mmu-miR-1930-5p	8
	mmu-mir-7119	9
mmu-mir-3470b		10
mmu-miR-3077-3p		40
mmu-miR-491-3p		41
mmu-mir-434		42
mmu-miR-128-2-5p		43
mmu-miR-434-3p		44
	mmu-miR-1950	45
	mmu-mir-12201	11
	mmu-miR-12201-5p	12
	mmu-miR-3109-3p	13
	mmu-miR-124-5p	14
mmu-miR-496a-5p		15
mmu-mir-12203		46
mmu-miR-12203-3p		47
mmu-miR-363-5p		48
	mmu-miR-7681-5p	49
	mmu-miR-103-1-5p	16
mmu-mir-1929		17
mmu-miR-7034-5p		50
mmu-mir-6409	mmu-miR-219c-3p	51
		18
	mmu-miR-6961-5p	52
	mmu-miR-6244	19
	mmu-miR-7065-5p	20
mmu-miR-5617-5p		21
	mmu-miR-7675-5p	53
	mmu-miR-7117-5p	22
mmu-mir-7023		23
	mmu-miR-6546-3p	54
mmu-miR-2139		24
mmu-miR-3102-5p		55
mmu-miR-871-3p		56
mmu-miR-8108		57
mmu-miR-3073a-3p		58
mmu-miR-5617		59
mmu-mir-871		60
	mmu-miR-7675	61
	mmu-mir-7117	25
	mmu-mir-6905	26
	mmu-miR-6905-5p	27
	mmu-miR-5129-3p	28
	mmu-mir-7065	29
	mmu-mir-1950	30
	mmu-miR-5129	31
	mmu-miR-365-1-5p	32
		33

[0113] 35 miRNA had statistically significant ($p<0.05$) expression levels, with all 35 miRNAs being significantly

downregulated in the HSSD exosomes when compared to exosomes from the static and LSLD groups (FIGS. 7B-7E). Compounding on these results, it was often found that when the precursor miRNA was found to be up- or downregulated, the mature miRNA was also found to be similarly expressed. Differential Exosomal miRNA Regulate Specific Pathways [0114] Upon gene ontology analysis, the significantly downregulated miRNAs in HSSD exosomes compared to static were associated with 218 potential gene targets, and these targets were enriched for 178 GO terms (Tables 2A (FIG. 8) and 2B, below). To find the most specific biological processes among these, terminal GO terms/nodes were identified. This process yielded 46 specific GO terms (FIG. 9A, solid bars) 32 of which were found to be significantly enriched (FDR<0.05, solid, blue bars). Regulation of BMP signaling, actin-filament based processes, and muscle cell apoptosis were noted and are programs highly associated with musculoskeletal development and repair.

TABLE 2b

HSSD v LSLD Enriched GO Terms			
HSSD v LSLD Enriched GO Terms			
GO Term	Description	P-value	FDR q-value
GO: 0060627	regulation of vesicle-mediated transport	2.68E-05	3.93E-01
GO: 0017157	regulation of exocytosis	4.92E-05	3.60E-01
GO: 0099177	regulation of trans-synaptic signaling	8.30E-05	4.06E-01
GO: 0050804	modulation of chemical synaptic transmission	8.30E-05	3.04E-01
GO: 0051641	cellular localization	9.70E-05	2.85E-01
GO: 0043506	regulation of JUN kinase activity	1.31E-04	3.19E-01
GO: 1903305	regulation of regulated secretory pathway	1.35E-04	2.83E-01
GO: 2000300	regulation of synaptic vesicle exocytosis	1.51E-04	2.77E-01
GO: 1902803	regulation of synaptic vesicle transport	1.81E-04	2.96E-01
GO: 0046928	regulation of neurotransmitter secretion	4.49E-04	6.59E-01
GO: 0017158	regulation of calcium ion-dependent exocytosis	4.65E-04	6.20E-01

TABLE 2b-continued

HSSD v LSLD Enriched GO Terms		HSSD v LSLD Enriched GO Terms	
GO Term	Description	P-value	FDR q-value
GO: 0006590	thyroid hormone generation	5.73E-04	7.01E-01
GO: 0098693	regulation of synaptic vesicle cycle	6.67E-04	7.52E-01
GO: 0007250	activation of NF-kappaB-inducing kinase activity	6.86E-04	7.19E-01
GO: 0035729	cellular response to hepatocyte growth factor stimulus	6.86E-04	6.71E-01
GO: 0043900	regulation of multi-organism process	7.53E-04	6.90E-01
GO: 0080134	regulation of response to stress	7.79E-04	6.73E-01
GO: 0043901	negative regulation of multi-organism process	7.99E-04	6.51E-01
GO: 0043549	regulation of kinase activity	8.78E-04	6.78E-01
GO: 0045088	regulation of innate immune response	9.31E-04	6.83E-01
GO: 0051240	positive regulation of multicellular organismal process	9.39E-04	6.56E-01
GO: 0035728	response to hepatocyte growth factor	9.42E-04	6.28E-01

[0115] The downregulated miRNAs in HSSD exosomes compared to LSLD were associated with 53 gene targets (Tables 2A (FIG. 8) and 2B). In a GO analysis of these 53 gene targets, 22 GO terms were enriched (Tables 2A (FIG. 8) and 2B), and there were 11 specific processes/terminal GO terms yielded (FIG. 9A, striped bars), several of which suggested a role in synaptic vesicle processes. Of the 11 final GO terms, 3 were found to be significantly enriched (FDR<0.05, striped, blue bars).

[0116] Once categorized, the majority of enriched GO terms involved developmental processes (FIGS. 9B and 9C). Several other enriched GO terms suggested a general role in regulating processes associated with cellular signaling, metabolism, inflammation, and transcriptional regulation, suggesting that the exosomes found in this study had the ability to impart broad, systemic changes to a host of tissues and cell types (Tables 3A and 3B, below).

TABLE 3a

Gene Ontology Categories HSSD vs Static					
Description	Reviewer 1	Reviewer 2	Reviewer 3	Reviewer 4	Final
Angiogenesis (GO: 0001525)	Development	Development	Development	Development	Development
Cardiac Development (GO: 0048738)	Muscle	Muscle	Development	Muscle	Muscle
Synaptic Vesicle Exocytosis (GO: 2000300)	Signaling	Neural	Neural	Neural	Neural
Transmembrane Transport (GO: 0034762)	Signaling	Signaling	Signaling	Signaling	Signaling
Postsynaptic Membrane Potential (GO: 0060078)	Signaling	Neural	Neural	Neural	Neural
IGF Signaling (GO: 0043567)	Signaling	Signaling	Signaling	Signaling	Signaling

TABLE 3a-continued

Description	Gene Ontology Categories HSST vs Static				
	Reviewer 1	Reviewer 2	Reviewer 3	Reviewer 4	Final
Cell Migration (GO: 0030336)	Development	Development	Development	Development	Development
Multi-organism Processes (GO: 0043901)	Development	Development	Signaling	Development	Development
Muscle Cell Apoptosis (GO: 0010660)	Muscle	Muscle	Muscle	Muscle	Muscle
Heart Contraction (GO: 0002026)	Muscle	Muscle	Muscle	Muscle	Muscle
Testosterone Secretion (GO: 2000843)	Signaling	Signaling	Signaling	Signaling	Signaling
Kinase Activity (GO: 0033674)	Metabolism	Metabolism	Signaling	Metabolism	Metabolism
Apoptotic Process (GO: 0043065)	Development	Development	Development	Development	Development
Growth Rate (GO: 0045967)	Development	Development	Development	Development	Development
Ras Signal Transduction (GO: 0046579)	Signaling	Signaling	Signaling	Signaling	Signaling
Branching Structure Morphogenesis (GO: 0060688)	Development	Development	Development	Development	Development
Amyloid-Beta Response (GO: 1904646)	Neural	Neural	Signaling	Neural	Neural
Oocyte Development (GO: 0060281)	Development	Development	Development	Development	Development
Astrocyte Differentiation (GO: 0048710)	Neural	Neural	Neural	Neural	Neural
Wound Healing (GO: 0042060)	Development	Inflammation	Inflammation	Inflammation	Inflammation
MAPK Cascade (GO: 0043410)	Signaling	Signaling	Signaling	Signaling	Signaling
Protein Secretion (GO: 0050714)	Signaling	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation
Organ Morphogenesis (GO: 2000027)	Development	Development	Development	Development	Development
Macromolecule Biosynthetic Process (GO: 2000113)	Development	Metabolism	Metabolism	Metabolism	Metabolism
Oligodendrocyte Differentiation (GO: 0048715)	Neural	Neural	Neural	Neural	Neural
Protein Phosphorylation (GO: 0001932)	Metabolism	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation
Actin Cytoskeleton Organization (GO: 0030036)	Development	Development	Muscle	Development	Development
BMP Signaling Pathway (GO: 0030513)	Development	Signaling	Development	Development	Development
Signal Transduction (GO: 0009968)	Signaling	Signaling	Signaling	Signaling	Signaling
Systemic Blood Pressure (GO: 0002025)	Signaling	Signaling	Inflammation	Signaling	Signaling
Actin Filament-Based Process (GO: 0032970)	Development	Development	Muscle	Development	Development

TABLE 3a-continued

Description	Gene Ontology Categories HSSD vs Static				
	Reviewer 1	Reviewer 2	Reviewer 3	Reviewer 4	Final
Cellular Component Organization (GO: 0051128)	Development	Development	Development	Development	Development
Learning or Memory (GO: 0007611)	Development	Neural	Neural	Neural	Neural
Ion-dependent Exocytosis (GO: 0017158)	Signaling	Signaling	Signaling	Signaling	Signaling
Transcription Regulation (GO: 0045944)	Metabolism	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation
Cardiac Muscle Hypertrophy (GO: 0010611)	Muscle	Muscle	Muscle	Muscle	Muscle
Metabolic Process (GO: 0051172)	Metabolism	Metabolism	Metabolism	Metabolism	Metabolism
Glia Cell Proliferation (GO: 0060251)	Neural	Neural	Neural	Neural	Neural
Neuron Projection Morphogenesis (GO: 0048812)	Neural	Neural	Neural	Neural	Neural
Cell Cycle Regulation (GO: 0051726)	Metabolism	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation
Forebrain Development (GO: 0030900)	Neural	Development	Development	Development	Development
Gene Expression (GO: 0010629)	Metabolism	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation	Transcriptional Regulation
GTPase Activity (GO: 0043547)	Metabolism	Metabolism	Signaling	Metabolism	Metabolism
G Protein-coupled Receptor (GO: 0008277)	Signaling	Signaling	Signaling	Signaling	Signaling
Gliogenesis (GO: 0014015)	Neural	Neural	Neural	Neural	Neural
Synaptic Plasticity (GO: 0048167)	Neural	Neural	Neural	Neural	Neural

TABLE 3b

Description	HSSD v. LSLD HSSD vs LSLD				
	Reviewer 1	Reviewer 2	Reviewer 3	Reviewer 4	Final
Synaptic Vesicle Regulation (GO: 0098693)	Neural	Neural	Neural	Neural	Neural
NF- κ B Kinase Activity (GO: 0007250)	Inflammation	Inflammation	Inflammation	Inflammation	Inflammation
Thyroid Hormone Generation (GO: 0006590)	Metabolism	Metabolism	Metabolism	Metabolism	Metabolism
Innate Immune Regulation (GO: 0045088)	Inflammation	Inflammation	Signaling	Inflammation	Inflammation
HGF Response (GO: 0035729)	Development	Signaling	Signaling	Signaling	Signaling
Multicellular Processes (GO: 0051240)	Development	Development	Signaling	Development	Development

TABLE 3b-continued

Description	HSSD v. LSLD HSSD vs LSLD				
	Reviewer 1	Reviewer 2	Reviewer 3	Reviewer 4	Final
Multi-organism Processes (GO: 0043901)	Development	Development	Signaling	Development	Development
Ion-dependent: Exocytosis (GO: 0017158)	Signaling	Signaling	Neural	Signaling	Signaling
JUN Kinase Regulation (GO: 0043506)	Signaling	Signaling	Signaling	Signaling	Signaling
Synaptic Vesicle Transport (GO: 1902803)	Neural	Neural	Neural	Neural	Neural
Synaptic Vesicle Exocytosis (GO: 2000300)	Neural	Neural	Neural	Neural	Neural

[0117] The health benefits of exercise are widely recognized, with exercise being an effective strategy to promote healthy aging by preventing several chronic diseases including metabolic disorders, cardiovascular disease, sarcopenia, and bone loss (Booth, et al., 2012 *Compr Physiol* 2 (2): 1143-1211; Garatachea, et al., 2015 *Rejuvenation Res* 18 (1): 57-89; Cartee, et al., 2016 *Cell Metab* 23 (6): 1034-1047; Beckwee, et al., 2019 *J Nutr Heal Aging* 23 (6): 494-452; Stefani and Galanti, 2017 *Adv Exp Med Biol* 123-141). Exercise improves overall health during aging, likely by a combination of molecular and biomechanical mechanisms, largely driven by preservation of skeletal muscle (Distefano and Goodpaster, 2018 *Perspect Med* 8 (3)). Complete understanding of this process has been impeded by complexities arising from the complex, whole-body-integrated effects of exercise, which obscure specific relationships between skeletal muscle, cartilage and bone health during aging (Kirby, et al., 2012 *Circ Res* 111 (2); Nicklas, et al., 2008 *Aging Clin Exp Res* 20 (4)). Dissecting such mechanisms could potentially lead to a targeted pharmaceutical therapy (as an adjunct to exercise) that could be especially efficacious in older individuals, where exercise is often challenging.

[0118] Although it was previously demonstrated that in vitro mechanical strain and in vivo treadmill exercise can further increase the regenerative capacity of muscle progenitor cells (Ambrosio, et al., 2010 *Tissue Eng Pt A* 16 (3): 839-849), the mechanism underlying this improvement is still unclear. While mechanical disruption of the cell membrane and influxes of calcium during skeletal muscle contraction have been shown to induce exosome release (Savina, et al., 2003 *J Biol Chem* 278 (22): 20083-20090; Bittel and Jaiswal, 2019 *Front Physiol* 10 <https://pubmed.ncbi.nlm.nih.gov/31379590/>), contradictions in the literature remain as to whether exercise stimulates an increase in skeletal muscle-derived exosomes released into the local tissue and into the bloodstream. In one study, there was no significant change in skeletal muscle exosomes in the bloodstream immediately following an hour of endurance exercise (Nielsen, et al., 2019 *J Clin Endocrinol Metab* 104 (10): 4804-4814). In contrast, a more recent study found an increase in skeletal muscle exosomes in circulation after 30 minutes of moderate exercise (Rigamonti, et al., 2020 *Int J Obes* 44 (5): 1108-1118), suggesting that skeletal muscle may partially contribute to the exercise-induced increase in

circulating exosomes. Mechanical strain of myoblasts may cause the increased production of exosomes with pro-regenerative functions. The results described herein demonstrate that cyclical strain, an ex vivo exercise mimetic, results in increased production of C2C12 myoblast-derived exosomes with enhanced proliferative and myogenic functions.

[0119] Furthermore, the clinical application of mesenchymal stem cells (MSCs) remains limited due to regulatory hurdles and the lack of definitive guidelines for optimizing efficacy and safety. Good manufacturing practice (GMP)-grade stem cells are challenging to produce because of donor heterogeneity, passage limits and incompletely understood factors influencing their efficacy in different applications (Ährlund-Richter, et al., 2009 *Cell Stem Cell* 4 (1): 20-26; Truong, et al., 2019 *Adv Exp Med Biol* 1084:109-128), thus making it difficult to achieve uniformity between batches. These issues highlight the need for an alternative approach that can replicate the benefits of stem cell therapy, yet minimizing potential risks and regulatory challenges, with exosomes presenting a promising alternative.

[0120] Ultimately, the development of exosome-based therapeutics will require reproducible production of homogeneous exosome suspension, which can be optimized for defined clinical applications. While in vitro cell culture systems do not fully recapitulate in vivo conditions, a scalable and highly reproducible in vitro exosome production platform could ultimately enable efficient development of GMP-grade exosome-based therapeutics. Exosomes hold promise in the area of regenerative medicine for several reasons (Cobelli, et al., 2017 *Ann NY Acad Sci* 1410 (1): 57-67; Tao, et al., 2018 *Adv Sci* 5 (2): 1700449). For instance, exosome surface receptors can be engineered for targeted delivery of cargo to specific tissues. In addition, exosomes can be modified to contain specific therapeutic cargo (i.e., regulatory RNAs, proteins, or drugs).

[0121] This study is innovative, in that an in vitro bioreactor was utilized to simulate the effects of mechanical strain on exosome production from myoblast cells during exercise. The results build upon the investigated changes in exosome production and miRNA expression from skeletal muscle in response to in vivo exercise (Gomes, et al., 2014 *Biomarkers* 19 (7): 585-589) by providing insight into the effects of mechanical stimulation on exosome production from myoblast progenitor cells. Upon gene ontology investigation,

several differentially expressed miRNAs, including miR-146b-5p, miR-183-5p, miR-210-3p, and miR-324-5p, which have previously described roles in myogenesis (Lee, et al., 2020 *BMC Mol Cell Biol* 21 (1): 1-13; Liu, et al., 2020 *Mol Ther Nucl Acids* 22:722-732), osteogenesis (Xie, et al., 2017 *Sci Reports* 7 (1): 1-16), and cellular aging (Davis, et al., 2017 *Tissue Eng—PLA* 23 (21-22): 1231-1240) were identified in HSSD exosomes, suggesting that these miRNAs may also modulate musculoskeletal adaptations to mechanical strain. However, despite the HSSD exosomes showing differential expression of multiple miRNAs, this did not result in any functional changes being observed in the HSSD group in the current study. Exosomes transport diverse cargo comprised of not only miRNAs, but other DNA, RNAs, cytokines, proteins, and lipids (Kalluri and LeBleu, 2020 *Science* 80 (367): 6478), such additional exosomal cargo may contribute to the phenotypic changes observed in this study in addition to miRNAs. Furthermore, only 32.9% of all miRNAs found in this study were annotated with gene ontology terms.

[0122] While resistance exercise is currently the most effective strategy for the prevention of age-related muscle decline, collecting exercise-induced exosomes from serum is difficult, because circulatory exosomes represent a highly heterogeneous population from diverse tissue types (Vagner, et al., 2019 *Proteomics* 19 (8): 1800167). Thus, cell-type specific exosomes may be generated in vitro toward the goal of producing a clinically translatable exosome therapeutic to be used as a pre- (i.e. prehabilitation) or post- (i.e. rehabilitation) surgical intervention to aid in tissue repair and

recovery. While physical therapy rehabilitation has long been known to improve musculoskeletal injuries and improve recovery timelines after surgery, prehabilitation is increasingly being utilized as a means to further improve the rehabilitation process (Jahic, et al., 2018 *Med Arch* 72 (6): 439-443; Carter, et al., 2020 *BMC Musculoskeletal Disord* 21 (1). Based on the instant findings, a major underlying component driving these effects of prehabilitation may in fact be mediated by the muscle-derived exosomes produced in response to exercise. These exosomes therefore hold the possibility of being administered to a patient as a prehabilitation treatment prior to surgery in place of exercise, to prepare the body for repair and recovery.

[0123] Given the many health benefits of exercise and the potential for exosomes to mediate these benefits, exercise-derived exosomes may have therapeutic applications. Indeed, exosomes that are released following exercise have recently been demonstrated to have cardioprotective (Bei, et al., 2017 *Basic Res Cardiol* 112 (4); Hou, et al., 2019 *Circ Res* 124 (9) and neuroprotective effects (Wang, et al., 2020 *Exp Neurol* 330). Mechanical strain is demonstrated herein to alter the number and function of myoblast-derived exosomes, and therefore may hold therapeutic promise for musculoskeletal repair and regeneration.

[0124] The present disclosure is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the disclosure in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

SEQUENCE LISTING

```

Sequence total quantity: 64
SEQ ID NO: 1      moltype = RNA length = 63
FEATURE
source
1..63
mol_type = genomic RNA
organism = Mus musculus

SEQUENCE: 1
atcagtcagg ctccctggcta aagttagt ttcagctgca tttagccaaa gcctgactgt 60
aag                                              63

SEQ ID NO: 2      moltype = RNA length = 20
FEATURE
source
1..20
mol_type = genomic RNA
organism = Mus musculus

SEQUENCE: 2
gggagtgctt cgtgcttctg                                              20

SEQ ID NO: 3      moltype = RNA length = 22
FEATURE
source
1..22
mol_type = genomic RNA
organism = Mus musculus

SEQUENCE: 3
cattttagcca aaggctgact gt                                              22

SEQ ID NO: 4      moltype = RNA length = 64
FEATURE
source
1..64
mol_type = genomic RNA
organism = Mus musculus

SEQUENCE: 4
tcttgcatgt gggcctgtgt gctataatgt cacttgctaa cagacgggct ctcatgctga 60
caga                                              64

SEQ ID NO: 5      moltype = RNA length = 80

```

-continued

```

FEATURE                               Location/Qualifiers
source                                1..80
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 5
ttcaatctgt ggtaactcaa ctgtgtgaca ttttgttctt tgtaagaagt gccgcagagt 60
ttgttagtgtt gccgatttag 80

SEQ ID NO: 6          moltype = RNA  length = 22
FEATURE                               Location/Qualifiers
source                                1..22
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 6
agtgcgcgac agttttagt gt 22

SEQ ID NO: 7          moltype = RNA  length = 95
FEATURE                               Location/Qualifiers
source                                1..95
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 7
ccctacacat ccatctttga ggttacaact tccccagtag actgtttcct gacattcctt 60
gtgagttgtt ctcacacctgg aagatgttgtt ggcgg 95

SEQ ID NO: 8          moltype = RNA  length = 22
FEATURE                               Location/Qualifiers
source                                1..22
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 8
ttagtattac atggccaatc tc 22

SEQ ID NO: 9          moltype = RNA  length = 22
FEATURE                               Location/Qualifiers
source                                1..22
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 9
acacctccatag tacctgcagc gt 22

SEQ ID NO: 10         moltype = RNA  length = 59
FEATURE                               Location/Qualifiers
source                                1..59
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 10
aaggactggg ggattgggtt cttttttttt aaaaaaaagaa aaaacacccgt ttccctccag 59

SEQ ID NO: 11         moltype = RNA  length = 22
FEATURE                               Location/Qualifiers
source                                1..22
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 11
tctgcatacata aggatatggt ca 22

SEQ ID NO: 12         moltype = RNA  length = 58
FEATURE                               Location/Qualifiers
source                                1..58
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 12
tggaaggatg cctcttgcaat atgttagcaga ggaggtatct gcagaggcctt cttggct 58

SEQ ID NO: 13         moltype = RNA  length = 21
FEATURE                               Location/Qualifiers
source                                1..21
                                         mol_type = genomic RNA
                                         organism = Mus musculus

SEQUENCE: 13
tggaaggatg cctcttgcaat a 21

SEQ ID NO: 14         moltype = RNA  length = 21
FEATURE                               Location/Qualifiers
source                                1..21

```

-continued

```

mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 14
tagggccatc tcatccagat a 21

SEQ ID NO: 15      moltype = RNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 15
cgtgttcaca gcggaccttg at 22

SEQ ID NO: 16      moltype = RNA length = 20
FEATURE          Location/Qualifiers
source           1..20
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 16
atcctgtctt tgccctctct 20

SEQ ID NO: 17      moltype = RNA length = 23
FEATURE          Location/Qualifiers
source           1..23
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 17
ggcttcttta cagtgctgcc ttg 23

SEQ ID NO: 18      moltype = RNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 18
cgagaattgc gtttggacaa tc 22

SEQ ID NO: 19      moltype = RNA length = 20
FEATURE          Location/Qualifiers
source           1..20
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 19
tgactgggaa ggaaatggcc 20

SEQ ID NO: 20      moltype = RNA length = 21
FEATURE          Location/Qualifiers
source           1..21
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 20
gggggcgtgg aattatcggt t 21

SEQ ID NO: 21      moltype = RNA length = 21
FEATURE          Location/Qualifiers
source           1..21
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 21
agtgttagcag gtaaaaccagg a 21

SEQ ID NO: 22      moltype = RNA length = 22
FEATURE          Location/Qualifiers
source           1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 22
cttacgaaag aatgaagagc aa 22

SEQ ID NO: 23      moltype = RNA length = 20
FEATURE          Location/Qualifiers
source           1..20
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 23
tgtccttctc ttccccccag 20

```

-continued

```

SEQ ID NO: 24      moltype = RNA  length = 21
FEATURE
source
1..21
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 24
gagcgaagcc caagcgccag a                                21

SEQ ID NO: 25      moltype = RNA  length = 58
FEATURE
source
1..58
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 25
cttacgaaag aatgaagagc aagctgtgtt ctgggcttg ttcattttt cgtgactc 58

SEQ ID NO: 26      moltype = RNA  length = 65
FEATURE
source
1..65
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 26
tgtgatctgg gggctcagct gaggataago ccgccttgtc accgctgtcc ttctttcc 60
cccag                                65

SEQ ID NO: 27      moltype = RNA  length = 70
FEATURE
source
1..70
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 27
gggagactgg gcagggttggg ttgaatgatt tgatcatgtt gtcaactaaa taaccttattc 60
tgcccgatag                                70

SEQ ID NO: 28      moltype = RNA  length = 23
FEATURE
source
1..23
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 28
actgggcagg ttgggttgaa tga                                23

SEQ ID NO: 29      moltype = RNA  length = 22
FEATURE
source
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 29
aatgtgcctg tgcatctttt cc                                22

SEQ ID NO: 30      moltype = RNA  length = 61
FEATURE
source
1..61
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 30
catggagtgt agcaggtaaa ccaggaatct ctctcagggc ttggttttcc tggcaca 60
g                                61

SEQ ID NO: 31      moltype = RNA  length = 74
FEATURE
source
1..74
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 31
gctttttctg catctaagga tatggtcatt taattgtttt tttccatgtt catctccctta 60
aatgcagaaa aagc                                74

SEQ ID NO: 32      moltype = RNA  length = 78
FEATURE
source
1..78
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 32
tcacacctaa atgtgggggc attggtattt tcaaaggcagc atttgaatg tgcctgtgca 60

```

-continued

tctcttccca cagtggtg	78
SEQ ID NO: 33	moltype = RNA length = 23
FEATURE	Location/Qualifiers
source	1..23
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 33	
agggactttt gggggcagat gtg	23
SEQ ID NO: 34	moltype = RNA length = 107
FEATURE	Location/Qualifiers
source	1..107
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 34	
tctcgcatgg ttcacgggag gacacacgct tttctgtgg tgattggga gcctgcctt	60
gttccccat tgtaaggaac tgcctgatt tctctgaat atggagt	107
SEQ ID NO: 35	moltype = RNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 35	
tggttcacgg gaggacacac gc	22
SEQ ID NO: 36	moltype = RNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 36	
gcaaaggcgc tggttccagc tg	22
SEQ ID NO: 37	moltype = RNA length = 23
FEATURE	Location/Qualifiers
source	1..23
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 37	
atggggagc tgggattggg cgt	23
SEQ ID NO: 38	moltype = RNA length = 110
FEATURE	Location/Qualifiers
source	1..110
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 38	
acaccctccc ccaggacagt aaagcacagt gatgaactct gagggcttt cacttcct	60
cggagttgtc ttggctctgt aatgtgaatc catgtggca	110
SEQ ID NO: 39	moltype = RNA length = 23
FEATURE	Location/Qualifiers
source	1..23
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 39	
ttcttaggact ttataagagca gag	23
SEQ ID NO: 40	moltype = RNA length = 126
FEATURE	Location/Qualifiers
source	1..126
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 40	
ggattctctg tgttagccttg gctgtcctgg cactcactct gtagaccagg ctggccttga	60
actcaaaaat tcacctgcct ctgcctcccg agtgctggga ctaaaggcat gcgctaccaa	120
tgcctcg	126
SEQ ID NO: 41	moltype = RNA length = 22
FEATURE	Location/Qualifiers
source	1..22
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 41	

-continued

```

ctgactccct gtttctccgc ag                                22
SEQ ID NO: 42      moltype = RNA  length = 22
FEATURE
source          Location/Qualifiers
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 42
cttatgcaag attcccttct ac                                22
SEQ ID NO: 43      moltype = RNA  length = 94
FEATURE
source          Location/Qualifiers
1..94
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 43
tcgactctgg gtttgaacca aagctcgact catggttga accattactt aattcgttgt 60
ttgaaccatc actcgactcc tggtcgaaac catc                                94
SEQ ID NO: 44      moltype = RNA  length = 23
FEATURE
source          Location/Qualifiers
1..23
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 44
ggggggccat gcactgttaag aga                                23
SEQ ID NO: 45      moltype = RNA  length = 22
FEATURE
source          Location/Qualifiers
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 45
tttgaaccat cactcgactc ct                                22
SEQ ID NO: 46      moltype = RNA  length = 21
FEATURE
source          Location/Qualifiers
1..21
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 46
agggtgcca tggtgtgttc a                                21
SEQ ID NO: 47      moltype = RNA  length = 63
FEATURE
source          Location/Qualifiers
1..63
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 47
tgcccgagggg atcgattgtct tctcccttttc cagcaaaggga tggaatctct ccctctggtc 60
tga                                63
SEQ ID NO: 48      moltype = RNA  length = 22
FEATURE
source          Location/Qualifiers
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 48
atggaatctc tccctctggc ct                                22
SEQ ID NO: 49      moltype = RNA  length = 22
FEATURE
source          Location/Qualifiers
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 49
caggtggaaac acgtatcaat tt                                22
SEQ ID NO: 50      moltype = RNA  length = 93
FEATURE
source          Location/Qualifiers
1..93
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 50
tttagaactgg gaggtttctt aggactttat agagcagaggg tttgcagcct gtgacactca 60
gctcatggag accttaggtgg ccttgggttc tga                                93

```

-continued

```

SEQ ID NO: 51      moltype = RNA  length = 21
FEATURE
source
1..21
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 51
tccgggaggg atggatgtgc t                                21

SEQ ID NO: 52      moltype = RNA  length = 92
FEATURE
source
1..92
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 52
gacgagcaat aacagcttagc gcgcatgcgt ggaccagaga caaagctgtc cccgtgtta 60
caaactgtgc gggtgaggat gtgtgctct ct                                92

SEQ ID NO: 53      moltype = RNA  length = 23
FEATURE
source
1..23
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 53
gtaagtgagg gcaageccttc tgg                                23

SEQ ID NO: 54      moltype = RNA  length = 64
FEATURE
source
1..64
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 54
tttgaatggg ggagctggga ttgggcgtgg agttggagg cctcacccctg tctgegcccc 60
tcag                                64

SEQ ID NO: 55      moltype = RNA  length = 24
FEATURE
source
1..24
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 55
agctgcgtg ctcctggtaa ctgc                                24

SEQ ID NO: 56      moltype = RNA  length = 22
FEATURE
source
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 56
gtgagtgccc agggtggggc tg                                22

SEQ ID NO: 57      moltype = RNA  length = 23
FEATURE
source
1..23
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 57
tgactggcac cattctggat aat                                23

SEQ ID NO: 58      moltype = RNA  length = 22
FEATURE
source
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 58
tctggggaggc agcgttagtta ca                                22

SEQ ID NO: 59      moltype = RNA  length = 22
FEATURE
source
1..22
mol_type = genomic RNA
organism = Mus musculus
SEQUENCE: 59
ttgatgtcca ctgtgaccat ag                                22

SEQ ID NO: 60      moltype = RNA  length = 57

```

-continued

FEATURE source	Location/Qualifiers
	1..57
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 60	
gttaagtgagg gcaagcccttc tgggttccata ccatcccagg cggcctcagc tctca	57
SEQ ID NO: 61	moltype = RNA length = 77
FEATURE source	Location/Qualifiers
	1..77
	mol_type = genomic RNA
	organism = Mus musculus
SEQUENCE: 61	
tgcagtgtc tattcagatt agtgcagtc atgtgaaata catatgactg gcaccatct	60
ggataatgtatgc	77
SEQ ID NO: 62	moltype = RNA length = 22
FEATURE source	Location/Qualifiers
	1..22
	mol_type = genomic RNA
	organism = Homo sapiens
SEQUENCE: 62	
cgtgtttcaca gcggaaccttg at	22
SEQ ID NO: 63	moltype = RNA length = 22
FEATURE source	Location/Qualifiers
	1..22
	mol_type = genomic RNA
	organism = Homo sapiens
SEQUENCE: 63	
cttatgcaag attcccttct ac	22
SEQ ID NO: 64	moltype = RNA length = 23
FEATURE source	Location/Qualifiers
	1..23
	mol_type = genomic RNA
	organism = Homo sapiens
SEQUENCE: 64	
ggggggccat acactgtacg aga	23

1. A composition comprising exosomes comprising at least one mechanoresponsive miRNA.
2. The composition of claim 1, wherein the exosomes are derived from mechanosensitive cells.
 3. (canceled)
 4. (canceled)
5. The composition of claim 1, wherein the exosomes are isolated from a cell sample after ex vivo exercise.
6. The composition of claim 5, wherein the exercise is achieved by a bioreactor creating mechanical strain on cells in the sample.
7. The composition of claim 5, wherein the exercise is low intensity or high intensity.
8. The composition of claim 1, wherein the exosomes are artificially synthesized.
9. The composition of claim 1, wherein the at least one mechanoresponsive miRNA is pro-regenerative.
10. The composition of claim 1, wherein the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-mir-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-miR-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20), mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22), mmu-miR-7117-3p (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24), mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-7117 (SEQ ID NO: 26), mmu-mir-6905 (SEQ ID NO: 27), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-miR-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), mmu-miR-365-1-5p (SEQ ID NO: 33), mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-mir-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-12203-3p (SEQ ID NO: 48), mmu-miR-363-5p (SEQ ID NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-mir-6409 (SEQ ID NO: 52), mmu-miR-5617-5p (SEQ ID NO: 53), mmu-mir-7023 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-miR-8108 (SEQ ID NO: 58),

mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

11. The composition of claim 10, wherein the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-mir-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-miR-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20), mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22), mmu-miR-7117-3p (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24), mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-7117 (SEQ ID NO: 26), mmu-mir-6905 (SEQ ID NO: 27), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-miR-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), and mmu-miR-365-1-5p (SEQ ID NO: 33).

12. The composition of claim 10, wherein the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-mir-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-12203-3p (SEQ ID NO: 48), mmu-miR-363-5p (SEQ ID NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-mir-6409 (SEQ ID NO: 52), mmu-miR-5617-5p (SEQ ID NO: 53), mmu-mir-7023 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-miR-8108 (SEQ ID NO: 58), mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

13. The composition of claim 1 for use in promoting regeneration in a subject.

14. The composition of claim 1 for use in the treatment of a musculoskeletal condition or disorder.

15. A method of preparing a composition comprising exosomes comprising at least one mechanoresponsive miRNA, the method comprising subjecting a mammal to exercise, obtaining a biological sample from the mammal, and isolating the exosomes from the sample.

16. A method of preparing a composition comprising exosomes comprising at least one mechanoresponsive miRNA, the method comprising exercising cells *ex vivo* and isolating the exosomes from the cells.

17. The method of claim 16, wherein the exercising is achieved by a bioreactor creating mechanical strain on the cells.

18. The method of claim 15, wherein the exercising is at low intensity or high intensity.

19. The method of claim 15, wherein the at least one mechanoresponsive miRNA is pro-regenerative.

20. The method of claim 15, wherein the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-mir-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-miR-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20), mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22), mmu-miR-7117 (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24), mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-6905 (SEQ ID NO: 26), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-miR-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), mmu-miR-365-1-5p (SEQ ID NO: 33), mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-mir-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-12203-3p (SEQ ID NO: 48), mmu-miR-363-5p (SEQ ID NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-mir-6409 (SEQ ID NO: 52), mmu-miR-5617-5p (SEQ ID NO: 53), mmu-mir-7023 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-miR-8108 (SEQ ID NO: 58), mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

21. The method of claim 20, wherein the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-344b (SEQ ID NO: 1), mmu-miR-3060-5p (SEQ ID NO: 2), mmu-miR-344b-3p (SEQ ID NO: 3), mmu-mir-12184 (SEQ ID NO: 4), mmu-mir-293 (SEQ ID NO: 5), mmu-miR-293-3p (SEQ ID NO: 6), mmu-mir-804 (SEQ ID NO: 7), mmu-miR-496a-3p (SEQ ID NO: 8), mmu-miR-1930-5p (SEQ ID NO: 9), mmu-mir-7119 (SEQ ID NO: 10), mmu-miR-1950 (SEQ ID NO: 11), mmu-mir-12201 (SEQ ID NO: 12), mmu-miR-12201-5p (SEQ ID NO: 13), mmu-miR-3109-3p (SEQ ID NO: 14), mmu-miR-124-5p (SEQ ID NO: 15), mmu-miR-7681-5p (SEQ ID NO: 16), mmu-miR-103-1-5p (SEQ ID NO: 17), mmu-miR-219c-3p (SEQ ID NO: 18), mmu-miR-6961-5p (SEQ ID NO: 19), mmu-miR-6244 (SEQ ID NO: 20), mmu-miR-7065-5p (SEQ ID NO: 21), mmu-miR-7675-5p (SEQ ID NO: 22), mmu-miR-7117-3p (SEQ ID NO: 23), mmu-miR-6546-3p (SEQ ID NO: 24),

mmu-mir-7675 (SEQ ID NO: 25), mmu-mir-7117 (SEQ ID NO: 26), mmu-mir-6905 (SEQ ID NO: 27), mmu-miR-6905-5p (SEQ ID NO: 28), mmu-miR-5129-3p (SEQ ID NO: 29), mmu-mir-7065 (SEQ ID NO: 30), mmu-mir-1950 (SEQ ID NO: 31), mmu-mir-5129 (SEQ ID NO: 32), and mmu-miR-365-1-5p (SEQ ID NO: 33).

22. The method of claim 20, wherein the at least one mechanoresponsive miRNA is the human equivalent of an miRNA selected from the group consisting of: mmu-mir-6378 (SEQ ID NO: 34), mmu-miR-6378 (SEQ ID NO: 35), mmu-miR-6403 (SEQ ID NO: 36), mmu-miR-7023-5p (SEQ ID NO: 37), mmu-mir-6539 (SEQ ID NO: 38), mmu-miR-1929-5p (SEQ ID NO: 39), mmu-mir-3470b (SEQ ID NO: 40), mmu-miR-3077-3p (SEQ ID NO: 41), mmu-miR-491-3p (SEQ ID NO: 42), mmu-mir-434 (SEQ ID NO: 43), mmu-miR-128-2-5p (SEQ ID NO: 44), mmu-miR-434-3p (SEQ ID NO: 45), mmu-miR-496a-5p (SEQ ID NO: 46), mmu-mir-12203 (SEQ ID NO: 47), mmu-miR-12203-3p (SEQ ID NO: 48), mmu-miR-363-5p (SEQ ID NO: 49), mmu-mir-1929 (SEQ ID NO: 50), mmu-miR-7034-5p (SEQ ID NO: 51), mmu-mir-6409 (SEQ ID NO: 52), mmu-miR-5617-5p (SEQ ID NO: 53), mmu-mir-7023 (SEQ ID NO: 54), mmu-miR-2139 (SEQ ID NO: 55), mmu-miR-3102-5p (SEQ ID NO: 56), mmu-miR-871-3p (SEQ ID NO: 57), mmu-mir-8108 (SEQ ID NO: 58), mmu-miR-3073a-3p (SEQ ID NO: 59), mmu-mir-5617 (SEQ ID NO: 60), and mmu-mir-871 (SEQ ID NO: 61).

23. (canceled)

24. (canceled)

* * * * *